

DUKE UNIVERSITY MEDICAL CENTER

CURRICULUM VITAE  
for  
Permanent Record  
and the  
Appointments and Promotions Committee

Date Prepared: FEB /2016

Name (complete with degrees): Daniel T. Laskowitz, MD, MHS

Primary academic appointment: Neurology

Primary academic department (not DUAP): Neurology

Secondary appointment(s): Anesthesiology (2000)  
Duke Clinical Research Institute (2008)  
Neurobiology (2001)

Duke ID #: 0056656

Present academic rank and title: Professor of Medicine (Neurology)

Date and rank of first Duke Faculty appointment: July 1, 1997 (Associate)

Medical Licensure: North Carolina License # 97-0087

Date of License: January 25, 1997

Specialty certification(s) and dates: American Board of Psychiatry and  
Neurology (#42855): April, 1996;  
Recertification August: 2006  
Recertification December: 2013

Neurosonology certification: March, 2003

ABPN subspecialty certification in  
Vascular Neurology (#308): July, 2006  
Recertification May, 2016

UCNS subspecialty certification in  
Neurocritical Care, December 2013

Citizen of USA: YES

Scholarly Societies: Sigma Xi

<u>Education</u>	<u>Institution</u>	<u>Date</u>	<u>Degree</u>
High School	Dobbs Ferry Public High School	1979-1983	Diploma
College	Brown University	1983-1987	Sc.B. (Honors)
Medical	Duke University School of Medicine	1987-1991	M.D.
Graduate	Duke University School of Medicine	1998-2003	M.H.S. (clinical research design)

Alpha Omega Alpha (Faculty inductee 2011)

Professional training and academic career:

<u>Institution</u>	<u>Position/Title</u>	<u>Dates</u>
Long Island Jewish Medical Center	Intern (Medicine)	1991-1992
University of Pennsylvania	Resident (Neurology)	1992-1995
Duke University Medical Center	Fellow (Stroke/Neurocritical Care)	1995-1997
Duke University Medical Center	Associate (Medicine)	1997-1998
Duke University Medical Center	Assistant Professor of Medicine (Neurology)	1998-2003
Duke University Medical Center	Director, Neurocritical Care Fellowship	1999- 2006
Duke University Medical Center	Associate Director, Multidisciplinary Neuroprotection Laboratories	2000-present
Duke University Medical Center	Director, Neurovascular Laboratory	2000-present
Duke University Medical Center	Assistant Professor of Neurobiology and Anesthesiology	2001-2003
Duke University Medical Center	Associate Professor of Medicine (Neurology)	2003-2006
Duke University Medical Center	Associate Professor Medicine with Tenure; Associate Professor of Anesthesiology	2006-2011
Duke University Medical Center	Professor of Medicine with Tenure; Professor of Anesthesiology, Professor of Neurobiology	2012- present
Duke University Medical Center	Vice Chair, Academic Affairs Development, Department Neurology	2013-present
Duke Clinical Research Institute	Director, Neuroscience Medicine	2016-present

## Publications

Refereed journals: (Refereed journals are scientific publications that have active editorial boards and a system of critical review of all submissions for publication.)

1. Lilley ER, Elion GT, Schold SC, **Laskowitz DT**, Friedman HS. "Therapeutic analysis of melphalan-resistant rhabdomyosarcoma xenograft TE-671MR". Cancer Research 51(15):3906-3909, 1991.
2. Escalone PR, McDonald WM, Doraiswami PM, Figiel GS, **Laskowitz DT**, Krishnan KR. "In-vivo stereological assessment of human cerebellar volume: effects of gender and age". American Journal of Neuroradiology 12(5):927-92, 1991
3. **Laskowitz DT**, Elion GT, Dewhirst MW, Griffith OW, Friedman HS. "Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion". International Journal of Hyperthermia 8(1):111-120, 1992.
4. **Laskowitz DT**, Elion GT, Dewhirst MW, Griffith OW, Friedman HS. "Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft". Radiation Research 129(2):218-223, 1992.
5. **Laskowitz DT**, Elion GT, Dewhirst MW, Griffith OW, Casero RA, Scott PA, Friedman HS. "Effects of glutathione or polyamine depletion on *in vivo* thermosensitization". International Journal of Hyperthermia 8(2):199-208, 1992.
6. Shedlack KJ, McDonald WM, **Laskowitz, DT**, Krishnan KR. "Geniculocalcarine hyperintensities on brain magnetic resonance imaging associated with visual hallucinations in the elderly". Psychiatry Research 54(3):283-293, 1994.
7. Crino PB, Zimmerman R, **Laskowitz DT**, Raps EC, Rostami AM. "Magnetic Resonance Imaging of the cauda equina in Guillain-Barre syndrome". Neurology 44(7): 1334-1336, 1994.
8. **Laskowitz DT**, Sperling MR, French JA, O'Connor MJ. "The syndrome of frontal lobe epilepsy: characteristics and surgical management". Neurology 45(4):780-787, 1995.
9. **Laskowitz DT**, Goel S, Bennett E, Matthew WD. "Apolipoprotein E suppresses glial secretion of TNF $\alpha$ ". Journal of Neuroimmunology 76: 70-74, 1997.
10. **Laskowitz DT**, Sheng H, Bart R, Joyner KA, Roses AD, Warner DS. "Apolipoprotein E deficient mice have increased susceptibility to focal cerebral ischemia". Journal of Cerebral Blood Flow and Metabolism 17: 753-758, 1997.
11. **Laskowitz DT**, Roses AD. "Apolipoprotein E: an expanding role in the neurobiology of disease". Alzheimer's Reports 1(1): 5-12, 1998.
12. **Laskowitz DT**, Matthew WD, Bennett ER, Schmechel DE, Herbstreith MH, Goel S, McMillian MK. "Apolipoprotein E suppresses LPS-stimulated microglial nitric oxide production". Neuroreport 9(4), 1998.

13. Sheng H, **Laskowitz DT**, Bennett E, Schmechel DE, Bart RD., Saunders AM, Pearlstein RS, Roses AD, Warner DS. "Apolipoprotein E isoform specific differences in outcome from focal ischemia in transgenic mice". Journal of Cerebral Blood Flow and Metabolism 18:361-366, 1998.
14. **Laskowitz DT**, Horsburgh K, Roses AD. "Apolipoprotein E and the CNS response to injury". Journal of Cerebral Blood Flow and Metabolism 18(5): 465-471, 1998.
15. **Laskowitz D**, Liu GT, Galetta SL. "Acute visual loss and other disorders of the eyes". Neurologic Clinics 16(2): 323-354, 1998.
16. **Laskowitz DT**, Grocott H, Hsia A, Copeland KR. "Serum markers of cerebral ischemia". Journal of Stroke and Cerebrovascular Disease 7(4): 234-241, 1998.
17. Bart RD, Sheng H, **Laskowitz DT**, Pearlstein RD, Warner DS. "Regional cerebral blood flow in apolipoprotein E deficient vs wildtype mice undergoing middle cerebral artery occlusion". Neuroreport 11(3): 2615-2620, 1998.
18. Newman MF, **Laskowitz DT**, Saunders A, Grigore A, Grocott H. "Genetic predictors of neurologic and neuropsychologic injury and recovery". Seminars in Cardiovascular and Vascular Anesthesia 3(1):1-14, 1999.
19. Bushnell CD, Phillips-Bute BG, **Laskowitz DT**, Lynch J, Chilikuri V, Borel CO. "Survival and outcome following endotracheal intubation for acute stroke". Neurology 52(7):1374-1380,1999.
20. Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, **Laskowitz DT**, Miler JM, Sloan MA, Berdan LG, MacAuley CM, Lincoff M, Deckers J, Topol EJ, Califf RM. "Stroke in patients with acute coronary syndromes: Incidences and outcomes in the PURSUIT trial". Circulation 99:2371-7, 1999.
21. Sheng H, **Laskowitz DT**, Mackensen GB, Kudo, M, Pearlstein RD, Warner DS. "Apolipoprotein E deficiency worsens outcome from global ischemia in the mouse". Stroke 30(5):1118-1123, 1999.
22. Sheng H, **Laskowitz DT**, Pearlstein RD, Warner DS. "Characterization of a recovery global cerebral ischemia model in the mouse". Journal of Neuroscience Methods 88:103-109, 1999.
23. Mahaffey KW, **Laskowitz DT**, Miller JM, MacAuley CM, Harrington RA. "Incidence of stroke in patients with acute coronary syndromes without persistent ST-segment elevations". Cardiology Review 17:15-24, 2000.
24. Wellons JC, Sheng H, **Laskowitz DT**, Mackensen GB, Pearlstein RD, Warner DS. "A comparison of strain-related susceptibility in two murine recovery models of cerebral ischemia". Brain Research 868(1):14-21, 2000.
25. **Laskowitz DT**, Lee DM, Staats HF. "Altered immune responses in apolipoprotein E-deficient mice". Journal of Lipid Research 41(4):613-620, 2000.
26. **Laskowitz DT**, Thekde S, Han D, Thekde A, Bennet ER. "Downregulation of glial activation by apolipoprotein E and apoE-mimetic peptides". Experimental Neurology, 167:74-85, 2001.

27. Olson DM, Borel CO, **Laskowitz DT** Moore DT McConell ES. "Quiet time: A nursing intervention to promote sleep in the neurocritical care unit". American Journal of Critical Care 11(2):74-78, 2001.
28. Lynch JR, Morgan D, Mance J, Matthew WD, **Laskowitz DT**. "Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response". Journal of Neuroimmunology 114:107-113, 2001.
29. Newman, MF, **Laskowitz DT**, White, WD, Kirchner, J, Grigore A, Grocott H, Stafford-Smith M, Reves JG, Sanders A. "Apolipoprotein E polymorphism and age at first coronary artery bypass graft". Anesthesia & Analgesia 92:824-829, 2001.
30. Misra UK, Gawdi G, McMillian MK, Pizzo SV, **Laskowitz DT**. "Apolipoprotein E and apoE-mimetic peptides initiate a calcium dependent signaling response in macrophage". Journal of Leukocyte Biology 70: 677-683, 2001
31. Pineda JA, Aono M, Sheng H, Lynch J, Wellons JC, **Laskowitz DT**, Pearlstein RD, Bowler, R, Crapo J, Warner DS. "Extracellular superoxide dismutase overexpression improves behavioural outcome from closed head injury in the mouse". Journal of Neurotrauma 18:625-634, 2001
32. Grocott HP, Newman MF, El-Moalem H, Bainbridge D, Butler AM, **Laskowitz DT** "Apolipoprotein E genotype differentially influences the pro and anti-inflammatory response to cardiopulmonary bypass". Journal of Thoracic and Cardiovascular Surgery 122: 622-624, 2001.
33. Newman MF, Booth JV, **Laskowitz DT**, Schwinn DA, Grocott HP, Mathew JP. "Genetic predictors of perioperative neurological and cognitive injury". Best Practices in Research and Clinical Anesthesiology 15: 247-276, 2001.
34. Newman MF, Grocott HP, Mathew JP, White WD, Landolfo K, Reves JG, **Laskowitz DT**, Mark DB Blumenthal JA. "Neurologic Outcome Research Group and Cardiothoracic Anesthesia Research Endeavors (CARE) Investigators of the Duke Heart Center. Report of the substudy assessing the impact of neurocognitive function on quality of life five years after cardiac surgery". Stroke, 32:2874-2881, 2001.
35. Lynch JR, Pineda J, Zhang L, Warner DS, Benveniste H, **Laskowitz DT**. "Apolipoprotein E affects the CNS response to injury and the development of cerebral edema". Annals of Neurology 51:113-117, 2002.
37. Stanley TO, Mackenson GB, Grocott HP, White WD, Blumenthal JA, **Laskowitz DT**, Landolfo KP, Reves JG, Mathew JP. "The impact of postoperative atrial fibrillation on neurocognitive outcome after coronary artery bypass graft surgery". Anesthesia Analgesia, 94:290-295, 2002.
38. Grigore AM, Grocott HP, Mathew JP, Philips-Bute B, Stanley TO, Butler A, Reves JG, Blumenthal JA, Newman MF, Clements FM, Grichnik K, Hilton AK, Scwinn DA, Babyak MA, Khatri P, Graffagnino C, **Laskowitz DT**, Saunders AM, Strittmatter WJ, Anderson RW, D'Amico TA, Glower DD, Harpole DH, Milano C, Smith PK, Wolfe WG . "The rewarming rate and increased peak temperature alter neurocognitive outcome after cardiac surgery", Anesthesia and Analgesia, 94:4-10, 2002
39. Morgan KT, Brown HR, Benavides G, Crosby L, Springer D, Yoon L, Easton M, Morgan D,

- Laskowitz DT**, Tyler R, “Toxicogenomics in human disease risk assessment”. Journal of Human and Ecological Risk Assessment 8(6): 1339-1353, 2002.
40. Sato Y, MD, **Laskowitz DT**, Newman M, Warner DS, Grocott H. “Cardiopulmonary Bypass Induces Cerebral Apoptotic Gene Expression in the Rat”. Anesthesia Analgesia, 94:1389-1394), 2002.
  41. Parra A, McGirt MJ, Sheng H, **Laskowitz DT**, Pearlstein RD, Warner DS. “Murine model of aneurysmal subarachnoid hemorrhage associated cerebral vasospasm: Methodological analysis”. Neurological Research, 24: 510-516, 2002.
  42. Aono M, Lee Y, Grant ER, Zivin RA, Pearlstein RD, Warner DS, Bennett ER, **Laskowitz DT**. “Apolipoprotein E protects against NMDA excitotoxicity”. Neurobiology of Disease, 11: 214-220, 2002.
  43. McGirt MJ, Parra A, Higuchi Y, Sheng H, **Laskowitz DT**, Oury T, Pearlstein RD, Warner DS. “Attenuation of cerebral vasospasm after subarachnoid hemorrhage in mice overexpressing extracellular superoxide dismutase”. Stroke, 33:2317-2323, 2002.
  44. McGirt MJ, Lynch JR Blessing R, Warner DS, Friedman AH, **Laskowitz DT**. “Serum Von Willebrand Factor, Matrix Metaloproteinase-9, and Vascular Endothelial Growth Factor Effectively Predict the Onset of Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage”. Journal of Neurosurgery 51: 1128-1135, 2002.
  45. Brown, CM, Wright E, Colton C, Sullivan PM, **Laskowitz, DT**, Vitek MP. “Apolipoprotein E isoform mediated regulation of nitric oxide release”. Free Radical Biology in Medicine 32: 1071-1075, 2002.
  46. McGirt, MJ, Lynch JR, Sheng H, **Laskowitz DT**, Pearlstein RD, Warner DS. “Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm following subarachnoid hemorrhage”. Stroke, 33(12):2950-6, 2002.
  47. Higuchi Y, Nelson GA, Vazquez M, **Laskowitz DT**, Slater JM, Pearlstein RD. “Apolipoprotein E expression and behavioural toxicology of high charge, high energy, particle radiation”. Radiation Research, 43, 219-224, 2002.
  48. **Laskowitz DT**, Lynch JR, Warner DS, Pineda J. “Apolipoprotein E modulates the CNS response to injury”. Journal of Neurochemistry 81:31, 2002.
  49. Aono M, Bennett ER, Kim KS, Massey GW, Myers J, Pearlstein RD, Warner DS, **Laskowitz DT**. “Protective effect of apolipoprotein E-mimetic peptides on NMDA excitotoxicity in primary rat neuronal/glial cultures”. Neuroscience 116:437-445, 2003.
  50. McGirt MJ, Mavropoulos JC, McGirt LY, Friedman AH, **Laskowitz DT**, Lynch JR. “Leukocytosis is an independent risk factor for cerebral vasospasm after aneurysmal subarachnoid hemorrhage”. Journal of Neurosurgery 98:1212-1216, 2003.
  51. Matthew JP, Grocott HP, Phillips-Bute B, Stafford-Smith M, **Laskowitz DT**, Rossignol D, Blumenthal J, Newman MF. “Lower endotoxin immunity predicts increased cognitive dysfunction in elderly patients after cardiac surgery”. Stroke 34:508-513, 2003.

52. Ti LK, Mackensen GB, Grocott HP, **Laskowitz DT**, Phillips-Bute BG, Milano CA, Hilton AK, Newman MF, Mathew JP. "Apolipoprotein E4 increases aortic atheroma burden in cardiac surgical patients". Journal of Thoracic & Cardiovascular Surgery. 125(1):211-2113, 2003.
53. Lee Y, Aono M, **Laskowitz, DT**, Warner DS, Pearlstein RD. "Apolipoprotein E protects against oxidative stress in mixed neuronal-glial cultures by reducing glutamate toxicity". Neurochemistry International 44(2):107-118, 2004.
54. Reynolds M, Kirchick H, Dahlen J, Anderberg J, McPherson P, Nakumara K, **Laskowitz DT**, Valkirs G, Beuchler K. "Early Biomarkers of stroke". Clinical Chemistry 49(10):1733-1739, 2003.
55. Lynch JR, Blessing R, White W, Grocott HP, Newman MF, **Laskowitz DT**. "A novel diagnostic test for acute stroke". Stroke 35:57-63, 2004.
56. Lynch JR, Tang W, Wang H, Vitek MP, Bennett ER, Sullivan P, Warner DS, **Laskowitz DT**. "ApoE and apoE-mimetic peptide modify the systemic and CNS inflammatory response". Journal of Biological Chemistry 278(49):48529-48533, 2003.
57. Lynch JR, **Laskowitz DT**. "A panel of serum markers for rapid diagnosis of stroke". Stroke, Apr, 2004.
58. McGirt, MJ, Blessing R, Nimjee S, Friedman AH, **Laskowitz DT**, Lynch JR. "Correlation of Serum Brain Natriuretic Peptide with Hyponatremia and Delayed Ischemic Neurological Deficits after Subarachnoid Hemorrhage". Neurosurgery 54: 1369-1774, 2004.
59. McGirt MJ, Woodworth GF, Lynch JR, **Laskowitz DT**. "Statins for the treatment of neurological injury: a role beyond cholesterol lowering". Clinical Neurosurgery 51: 320-328, 2004.
60. Lei B, Dawson H, Nnenweber, S, Warner DS, Bennett ER, Vitek MP, McKenna, S, **Laskowitz, DT**. "A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury". Experimental Neurology 192(1):109-116, 2005.
61. McAdoo J, Goldberg R, Warner DS, Vitek MP, **Laskowitz DT**. "Intrathecal administration of a novel apoE-derived therapeutic peptide improves outcome following perinatal hypoxic-ischemic injury". Neuroscience Letters 381(3), 305-308, 2005.
62. Matthew JP, Grocott HP, McCurdy JR, Ti, LK, Davis RD, **Laskowitz DT**, Podgoreanu MV, Swmainathan M, Lynch JR, Stafford-Smith M, White WD, Newman MD. "Pre-operative statin therapy does not reduce cognitive dysfunction after cardiopulmonary bypass". Journal of Cardiothoracic and Vascular Anesthesia 19(3), 294-299, 2005.
63. Moretti EW, Schwinn DS, Newman MF, Moulin VG, **Laskowitz DT**. "APOE Polymorphism is Associated with Sepsis Risk in Surgical Patient". Critical Care Medicine 33(11):2521-2526, 2005.
64. Lynch JR, Wang H, McGirt MJ, Floyd J, Friedman AH, Coon AL, Blessing R, Alexander MJ, Graffagnino C, **Laskowitz DT**. "Simvastatin reduces vasospasm after aneurysmal SAH: results of a pilot randomized clinical trial". Stroke 36(9), 2024-2026, 2005.

65. **Laskowitz DT**, Blessing R, Floyd J, White WD, Lynch JR. "Panel of biomarkers predicts stroke". Annals of the New York Academy of Sciences 1053:30-38, 2005.
66. McGirt MJ, Woodworth GF, Pradilla G, Legnani F, Warner DS, Tamargo R, Clatterbuck R, Lynch JR, **Laskowitz DT**, "Simvastatin attenuates experimental cerebral vasospasm and ameliorates serum markers of neuronal and endothelial injury in patients after subarachnoid hemorrhage: A dose-response effect dependent on endothelial nitric oxide synthase". Clinical Neurosurgery 52: 371-378, 2005.
67. Gao J, Wang H, Sheng H, Lynch JR, Warner DS, Durham L, Vitek, MP, **Laskowitz DT**. "A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage". Neurocritical Care, 4(1): 25-31, 2006.
68. Leinweber S, Sheng H, Pearlstein D, **Laskowitz DT**, Crapo J, Lynch JT, Warner DS. "Effects of a manganese (III) poroporphyrin catalytic antioxidant in a mouse closed head injury model". European Journal of Pharmacology, 531(1-3):126-132, 2006.
69. McGirt M, Tamargo R, Clatterbuck R, **Laskowitz DT**, Lynch JR. "HMG-CoA Reductase Inhibitors Reduce the Risk of Cerebral Vasospasm after Subarachnoid Hemorrhage: Multivariate Analysis of an Institutional Experience". Journal of Neurosurgery 105:671-674, 2006.
70. Warner DS, **Laskowitz DT**. "Changing Outcome from Aneurysmal Subarachnoid Hemorrhage: Another step closer". Anesthesiology. 104(4): 629-630, 2006.
71. Newman MF, Mathew JP, Grocott HP, Mackenson GB, **Laskowitz DT**, Blumenthal JA, Mark DB. "Central Nervous System Injury after Cardiac Surgery". Lancet 368: 694-703, 2006.
72. Wang H, Gao J, McDonagh DL, Warner DS, Lynch JR, **Laskowitz DT**, "Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage". Neurocritical Care 5(1)71-78, 2006.
73. **Laskowitz DT**, Fillit H, Yeung M, Toku K, Vitek M, "Apolipoprotein E-derived peptides reduce CNS inflammation- implications for therapy of neurological disease". Acta Neurol Scand 114:15-20, 2006.
74. Li F, Sempowski GD, McKenna SE, **Laskowitz DT**, Colton CA, Vitek MP, "Apolipoprotein E derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of sepsis". J Pharmacological and Experimental Therapeutics 318, 956-965, 2006.
75. Jauch, EC, **Laskowitz DT**, "D-Dimer Predicts Early Clinical Progression in Ischemic Stroke. Confirmation Using Routine Clinical Assays". Nature Clinical Practice Neurology 2(11): 590-591, 2006.
76. Mesis RG, Wang H, Lombard FW, Yates R, Vitek MP, Borel CO, Warner DS, **Laskowitz DT**. "Dissociation between vasospasm and functional improvement in a murine model of subarachnoid hemorrhage". Neurosurgical Focus 21(3), 1-7, 2006.
77. Takata K, Lombard F, Sheng H, **Laskowitz DT**, Borel C, Warner D, "A Rat Model of Cerebral Vasospasm Resulting in Chronic Motor and Neurocognitive Deficits Following Experimental SAH". Journal of Neurosurgical Anesthesiology 18(4):295, 2006.
78. Ely, WE, Shintani AK, Girard TD, Shintani A, Jackson JC, Gordon S, Thomason JW, Pun BT,



- Canonico AE, Light RW, Pandharipande P, **Laskowitz DT**. “Apolipoprotein E4 Polymorphism as a Genetic Predisposition to Delirium in Critically Ill patients”. Critical Care Medicine 35(1): 112-117, 2007. PMID: 17133176
79. Wang, H, Durham L, Dawson H, Song P, Warner DS, Sullivan PM, Vitek MP, **Laskowitz DT**, “An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction”. Neuroscience 144(4), 1324-1333, 2007.
80. Mace B, Wang H, Lynch JR, Sullivan P, Colton H, Morgan K, Renauld J. **Laskowitz DT** “Apolipoprotein E modifies the CNS Response to Injury via a Histamine-mediated Pathway” Neurological Research 29(3):243-250, 2007. PMID: 17509222
81. **Laskowitz DT**, McKenna SE, Song P, Wang H, Durham L, Christensen D, Vitek, MP “COG1410, A Novel Apolipoprotein E-Based Peptide, Improves Functional Recovery in a Murine Model of Traumatic Brain Injury”. Journal of Neurotrauma 24(7): 1093-1107, 2007. PMID: 17610350
82. Wang H, Lynch JR, Song P, Yates RB, Mace B, Warner DS, Guyton JR, **Laskowitz DT**. “Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury”. Experimental Neurology 206(1): 59-69, 2007.
83. Nicoletto HA, Ellis MW, **Laskowitz DT**, Kanter, RJ, Perry A, Burkman M. The use of transcranial Doppler during tilt table testing in children presenting with syncope”. Journal for Vascular Ultrasound 31(2):81-86, 2007.
84. **Laskowitz DT**, Vitek MP. Apolipoprotein E and Neurological Disease: “Therapeutic Potential and pharmacogenomic interactions”. Pharmacogenomics 8(8), 959-969, 2007. PMID: 17716229
85. Glickman S, Anstrom K, Chandra A, **Laskowitz DT**, Woods CW, Freedman SH, Beskow LM, Weinfurt K, Schulman K, Cairnes C. “Challenges in Enrollment of Minority, Pediatric, and Geriatric Patients in Emergency and Acute Care Clinical Research”. Annals of Emergency Medicine 51 (6), 775-780, 2008. PMID: 18191297
86. **Laskowitz DT**, Warner DS. “Statins in acute brain injury: Getting the Cart before the Horse”. Neurocritical Care 8(1):2-5, 2008. PMID: 18094941
87. James ML, Warner DS, **Laskowitz DT**. “Preclinical Models of Intracerebral Hemorrhage: A Translational Perspective”. Neurocritical Care 9(1): 135-52, 2008. PMID: 18058257
88. Gump W, **Laskowitz DT**. “Management of post-subarachnoid hemorrhage vasospasm”. Curr Atheroscler Rep 10(4):354-360, 2008. PMID: 18606107
89. Ivancevich NM, Pinton G, Nicoletto HA, Bennett ER, **Laskowitz DT**, Smith SW. “Real time 3D Contrast-Enhanced Transcranial Ultrasound and Aberration Correction”, Ultrasound in Medicine and Biology 34 (9) :1387-1395, 2008. PMID: 18395321
90. **Laskowitz DT**, Warner DS. “The Use of S100B as a Biomarker in Subarachnoid Hemorrhage: Clarity in its promise and limits”. Critical Care Medicine 36 (8): 2452-2453, 2008. PMID: 18664797

91. Margulies S, Hicks R, Ansel B, Bullock R, Clifford D, Clifton G, Conwit R, Dash P, Daz-Arrastia R, Dietrich WD, Dunn W, Emerson S, Fertig S, Hall E, Hoyt D, Janis S, Koroshetz W, **Laskowitz DT**, Meaney D, Morrison B, Noble L, Povlishock J, Robertson C, Rumm P, Soares H, Sopko G, Sullivan P, Wright D, Zafonte R. and NIH faculty, "Combination Therapies for Traumatic Brain Injury: Prospective Considerations". J Neurotrauma 26(6), 925-939, 2009. PMID: 19331514
92. James ML, Blessing R, Bennett ER, **Laskowitz DT**. "Apolipoprotein E modifies neurological outcome by affecting cerebral edema but not hematoma size after intracerebral hemorrhage in humans". J Stroke and Cerebrovas Dis 18(2), 144-149, 2009. PMID: 19251191
93. Smith SW, Ivancevich NM, Lindsey DB, Whitman J, Light E, Fronheiser MW, Nicoletto HA, **Laskowitz DT**. "The Ultrasound Brain Helmet: Feasibility study of Multiple Simultaneous 3D Scans of Cerebral Vasculature". Ultrasound in Medicine and Biology 35 (2): 329-338, 2009. PMID: 18947918
94. **Laskowitz DT**, Kasner SE, Saver J, Rummel KS, Jauch EC. "Clinical utility of a biomarker based diagnostic test in acute stroke: The Biomarker Rapid Assessment in Ischemic Injury (BRAIN) Study". Stroke 40(1):77-85, 2009. PMID: 18948614
95. Takata K, Sheng H, Borel CO, **Laskowitz DT**, Warner DS, Lombard FW. "Long term, cognitive dysfunction following experimental subarachnoid hemorrhage". Experimental Neurology 213:336-44, 2008. PMID: 18625221
96. Wang H, Christensen DJ, Vitek MP, Sullivan PM, **Laskowitz DT**. "APOE genotype affects outcome in a murine model of sepsis: implications for a new treatment strategy". Anesthesiology Intensive Care 37:38-45, 2009. PMID: 19157344
97. James ML, Sullivan PM, Lascola CD, Vitek MP, **Laskowitz DT**. "Pharmacogenomic effects of apolipoprotein E therapeutic in outcome after intracerebral hemorrhage". Stroke 40(2):632-9, 2009. PMID: 19109539
98. **Laskowitz DT**, Drucker RP, Parsonnet J, Cross PC, Gesundheit N. "Engaging students in dedicated research experiences and scholarship during medical school: The long term experiences at Duke and Stanford". Acad Med 85: 419-428, 2010. PMID: 20182114
99. Mathew JP, Mackensen GB, Phillips-Bute B, Grocott HP, Glower D, **Laskowitz DT**, Blumenthal JA, Newman MF. "Randomized, Double-Blinded, Placebo Controlled Study of Neuroprotection With Lidocaine in Cardiac Surgery". Stroke 40(3), 880-887, 2009. PMID: 19164788
100. Takata K, Sheng H, Borel CO, **Laskowitz DT**, Warner DS, Lombard FW. "Simvastatin treatment duration and cognitive preservation in experimental subarachnoid hemorrhage". J Neurosurgical Anesthesiology, 21:326-333, 2009. PMID: 19955895
101. James ML, Blessing R, Phillips-Bute BG, Bennett ER, **Laskowitz DT**. "S100B and BNP predict functional neurological outcome after intracerebral hemorrhage". Biomarkers 14(6), 695-702, 2009. PMID: 19505208
102. James ML, Wang H, Song PP, **Laskowitz DT**. "Brain natriuretic peptide improves functional outcome in a murine model of traumatic brain injury and ICH". J Neurotrauma 27(1): 217-228, 2010. PMID:

19955895

103. D'Onofrio G, Jauch E, Jagoda A, Allen M, Anglin D, Barsan W, Berger RP, Bobrow BJ, Boudreaux ED, Bushnell C, Chan YF, Currier G, Eggly S, Ichord R, Larkin GL, **Laskowitz DT**, Neumar RW, Newman-Toler DE, Quinn J, Shear K, Todd KH, Zatzick D, and NIH Federal Participants. "NIH Roundtable to Advance Research on Neurological and Mental Psychiatric Emergencies". Ann Emerg Med 56(5): 551-564, 2010.
104. El Husseini N, **Laskowitz DT**. "Clinical application of blood biomarkers in cerebrovascular disease". Expert Rev Neurother 10(2): 189-203, 2010. PMID: 20136376
105. Wible EF, **Laskowitz DT**. "Statins in traumatic brain injury". Neurotherapeutics 7(1): 62-73, 2010. PMID: 20129498
106. Granger C, **Laskowitz DT**. "Biomarkers in stroke: when will they improve care?". J Am Coll Cardiol 56(13):1054-1055, 2010. PMID: 20846605
107. **Laskowitz DT**, Kolls B. "Defining optimal cerebral perfusion pressures in acute brain injury: A step towards individualization of care?". Crit Care Med 38 (5):1385-1386, 2010. PMID: 20404636
108. Kolls B, **Laskowitz DT**. "A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease". Neurology 74; 2026-2027, 2010. PMID: 20548049
109. McDonagh DL, Mathew JP, White WD, Phillips-Bute B, **Laskowitz DT**, Podgoreanu MV, Newman MF. "Cognitive Function after Major Noncardiac Surgery, Apolipoprotein E4 Genotype, and Biomarkers of Brain Injury". Anesthesiology 112 (4): 852-859, 2010. PMID: 20216394
110. Chiarchiaro J, McLendon R, **Laskowitz DT**. "Progressive Multifocal Leukoencephalopathy with Occult Waldenström's Macroglobulinemia". J Clin Oncology, 28(36): 759-761, 2010. PMID: 20855833
111. **Laskowitz DT**, Kolls B. "Neuroprotection in Subarachnoid Hemorrhage". Stroke 41;S79-84, 2010. PMID: 20876512
112. Lindsey B, Light E, Nicoletto H, Bennett ER, **Laskowitz DT**, Smith S. "The ultrasound brain helmet: new transducers and volume registration for in vivo simultaneous multi-transducer 3D transcranial imaging". IEEE Trans Ultrason, Ferroelectr Freq Control 58(6): 1189-1202, 2011. PMID:21693401
113. **Laskowitz DT**, Drucker RP, Gesundheit N. "Does the Duration of a Scholarly Concentration Affect Medical Students' Productivity?". Acad Med 86(1):3, 2011.
114. **Laskowitz DT**, Song P, Wang H, Mace B, Sullivan PM, Vitek MP, Dawson H. "TBI exacerbates neurodegenerative pathology: improvement with an apoE based therapeutic". J Neurotrauma 27(11); 1983-1995, 2010. PMID: 20812776
115. Dawson HN, Cantillana V, Wang H, Vitek MP, Wilcock DM, Lynch JR, **Laskowitz DT**. "Loss of Tau Elicits Axonal Degeneration in a Mouse Model of AD". Neuroscience 169 (1):516-531, 2010. PMID: 20434528

116. Blake CM, **Laskowitz DT**, Wang H, Sullinger BA. "A reversible aptamer improves outcome and safety in murine models of stroke and intracranial hemorrhage". Oligonucleotides 21(1):11-19, 2011. PMID: 2114287
117. Cook S, Grochowski CO, Atherton A, **Laskowitz DT**, Pervaiz S, Buckley E, Kamei RK. "Developing physician leaders for over 50 years: The Duke medical student research experience in the US and Singapore". Acad Med 21 (1S):37-42, 2011.
118. Glickman S, Phillips S, Anstrom K, **Laskowitz DT**, Cairns CB. "Discriminative Capacity of Biomarkers for Acute Stroke in the Emergency Department". J Emer Med 41(3): 333-339, 2011. PMID: 20417054
119. **Laskowitz DT**, Dawson H, Lei, B, Wang H, Christensen DJ, Vitek MP, James ML. "The apoE-mimetic peptide, COG1410, improves functional recovery in a murine model of intracerebral hemorrhage". Neurocritical Care, 16(2): 316-326, 2012. PMID: 21989844
120. Indraswari F, Wang H, Lei B, James ML, Kernagis D, Warner DS, Dawson HN, **Laskowitz DT**. "Statins improve outcome in murine models of traumatic brain injury and intracranial hemorrhage: A translational approach". J Neurotrauma 29(7):1388-1400, 2012. PMID: 22233347
121. Kernagis DN, **Laskowitz DT**. "The evolving role of biomarkers in acute cerebrovascular disease". Ann Neurol 71(3): 289-303, 2012. PMID: 22451199
122. Philips S, Stanley L, Nicoletto H, Burkman M, **Laskowitz DT**, Cairns C. "Use of emergency department transcranial Doppler assessment of reperfusion after intravenous tPA for ischemic stroke". J Emer Med 42(1): 40-43, 2012 PMID: 19111426
123. El Husseini N, Goldstein LB, Peterson ED, Zhao X, Pan W, Olsen DM, Zimmer LO, Williams JW Bushnell C, **Laskowitz DT**. "Depression and antidepressant use after stroke and transient ischemic attack". Stroke 43(6):1609-1616, 2012. PMID: 2246133
124. Lei B, Mace B, Bellows ST, Sullivan PM, Vitek MP, **Laskowitz DT**, James ML. "Interaction between sex and apolipoprotein E genetic background in a murine model of intracerebral hemorrhage". Translational Stroke Research 3(1): S94-101, 2012 . PMID: 23935764.
125. Sun W, Peacock A, Becker J, Phillips-Bute, **Laskowitz DT**, James ML. "Correlation of leukocytosis with early neurological deterioration following supratentorial hemorrhage". J Clinical Neuroscience 2012. PMID: 22704946
126. James ML, Wang H, Cantillana V, Lei B, Kernagis DN, Dawson HN, Klamann LD, **Laskowitz DT**. "TT-301 inhibits microglial activation and improves outcome after central nervous system injury in adult mice". Anesthesiology 16(6): 1299-1311, 2012. PMID: 22461330
127. Sharma R, **Laskowitz DT**. "Biomarkers in Traumatic Brain Injury". Curr Neurol Neurosurg Rep 12(5):560-569, 2012. PMID: 22811071
128. El-Husseini N, **Laskowitz DT**, Peterson ED, Zhao X, Pan W, Olsen DM, Zimmer LO, Williams JW Bushnell C, Goldstein LB. "What causes disability after transient ischemic attack and minor stroke?". Stroke 43(12):e180, 2012. PMID: 23160877

129. Madenspacher JH, Azzam KM, Gong W, Gowdy KM, Vitek MP, **Laskowitz DT**, Remaley AT, Wang M, Fessler MB, Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity. Journal of Biological Chemistry 287(52): 43730-40, 2012 PMID: 23118226
130. Wang H, Anderson LG, Lascola CD, James ML, Venkatraman TN, Bennett ER, Acheson SK, Vitek MP, **Laskowitz DT**. “Apolipoprotein E mimetic peptides improve outcome after focal ischemia”, Experimental Neurology 17(1):67-74, 2013. PMID: 2321988
131. Wang B, Dawson H, Wang H, Kernagis D, Kolls, BK, Yao L, **Laskowitz DT**, “Lacosamide improves outcome in a murine model of traumatic brain injury”, Neurocritical Care 9(1):125-34, 2013 PMID: 23269559
132. Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, Bihorac A, Birkhahn R, Cely CM, Chawla LS, Davison DL, Feldkamp T, Forni LG, Gong MN, Gunnerson KJ, Haase M, Hackett J, **Laskowitz DT**, Lissauer ME, Marx G, McCullough PA, Mullaney S, Ostermann M, Rimmele T, Shapiro NI, Shaw AD, Shi J, Sprague AM, Vincent JL, Vinsonneau C, Wagner L, Walker MG, Wilkerson RG, Zacharowski K, Kellum JA. “Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury”, Crit Care 17(1): 2013 PMID: 23388612
133. Sankalp G, **Laskowitz DT**. “Vein of Galen aneurysm mimicking pineal mass in a young adult”, Neurology e240, 2013 PMID: 23713094
134. Lei B, Dawson HN, Roulhac-Wilson B, Wang H, **Laskowitz DT**, James ML, Tumor necrosis factor alpha antagonism improves neurological recovery in murine intracerebral hemorrhage. J Neuroinflammation 10(1): 2013 PMID: 23962089
135. Lindsey BD, Nicoletto HA Bennett ER, **Laskowitz DT**, Smith SW. Simultaneous Bilateral Real-Time 3-D Transcranial Ultrasound Imaging At 1 MHz Through Poor Acoustic Windows. Ultrasound Med Biol. 39(4):721-734, 2013 PMID: 23415287
136. Guptill JT, Mehta RH, Armstrong PW, Horton J, **Laskowitz D**, James S, Granger CB, Lopes R. Stroke After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction : Timing, Characteristics, and Clinical Outcomes. Circulation: Cardiovascular Interventions 6(2):176-183, 2013, PMID: 2354964
137. Gokhale S, **Laskowitz DT**. ApoE and outcome after Traumatic Brain Injury”. Clin. Lipidol. 8(5): 561-571, 2013
138. Sun W, Krantz P, Oan W, Williamson R, **Laskowitz DT**, James ML. Predictors of late neurological deterioration after spontaneous intracranial hemorrhage”. Neurocritical Care 19(3):299-305, 2013 PMID: 23979796
139. Sharma R, Macy S, Bennett E, **Laskowitz DT**. “A Blood-Based Biomarker Panel to Detect Acute Stroke”. J Stroke Cerebrovas Dis 23(5):910-918, 2014 PMID: 24119630
140. Mathew JP, White WD, Schinderle DB, Podgoreanu MV, Berger M, Milano CA, **Laskowitz DT**, Stafford-Smith M, Blumenthal JA, Newman MF. “Intra-operative Magnesium Administration does not

- improve neurocognitive function after cardiac surgery” *Stroke* 44(12):3407-13, 2013 PMID: 24105697
141. **Laskowitz DT**, Dawson HN,. Genetic Influences and Neuropathological Sequelae of Repetitive Brain Injury *Annals of Neurology* 75(4):617-618,2014 PMID: 24243027
  142. Williamson RA, Phillips-Bute BG, McDonagh DL, Gray MC, Zomorodi AR, Olson DM, Britz GW, **Laskowitz DT**, James ML “Predictors of extraventricular-drain associated ventriculitis” *J Crit Care* 29 (1); 29- 77-82, 2014 PMID: 24125770
  143. Umeano O, Philips-Bute B, Hailey C, Sun W, Gray MC, Roulhac-Wilson B, McDonagh D, Kranz PG, **Laskowitz DT**, James ML. “Gender and Age Interact to Affect Early Outcome after Intracerebral Hemorrhage” *PLOS ONE*, 8(11)2013, PMID: 24312335
  144. Lindsey BD, Nocoletto H, Bennett ER, **Laskowitz DT**, Smith SW, “3D Transcranial ultrasound imaging with bilateral phase aberration correction of multiple isoplanatic patches: A pilot clinical study with microbubble contrast enhancement”, *Ultrasound in Medicine & Biology*, 34(9):90-101, 2014, PMID: 24239360
  145. Wang H, James ML, Venkatraman TN, Wilson LJ, Lyuboslavsky P, Myers SJ, Lascola CD, **Laskowitz DT**, ‘pH sensitive NMDA inhibitors improve outcome in a murine model of SAH”, *Neurocritical Care* 20(1):119-131, 2014 PMID 24420693
  146. El-Husseini N, **Laskowitz DT**, “The role of neuroendocrine pathways in prognosis after stroke”, *Exper Rev Neurother* 14(2): 217-232, 2014 PMID: 24428141
  147. Mathew JP, **Laskowitz DT**, Newman MF “Response, Intra-operative Magnesium Administration does not improve Neurocognitive Function after Cardiac Surgery”, *Stroke*, 45(3):e45, 2014 PMID: 24448987
  148. Terrell TR, Cox CB, Bielak K, Casmus R, **Laskowitz D**, Nichols G. “Sports Concussion Management” *Southern Medical Journal*, 107(2)126-135, 2014: PMID: 24926680
  149. Morandi A, Hughes CG, Thompson JL, Pandharipande PP, Shintani AK, Vasilevskis EE, Han J, Caskson JC, **Laskowitz DT**, Bernard GR, Ely EW Statins and Delerium during critical illness: A multicenter, prospective cohort study” *Critical Care Medicine* PMID: 42(8): 1899-1909; 2014 PMID: 24810528
  150. Xie G, **Laskowitz DT**, Turner EL, Egger JR, Shi P, Ren F, Gao W, Wu Y. Baseline Health-Related Quality of Life and 10-Year All-Cause Mortality among 1739 Chinese Adults. *PLoS One*. 9(7), 2014 PMID: 25007092
  151. Lei B, Sheng H, Wang H, Lascola CD, Warner DS, **Laskowitz DT**, James ML, “Intrastriatal injection of autologous blood or clostridial collagenase as murine models of intracerebral hemorrhage” *J Vis Exp* 89: 2014, PMID: 25046028
  152. Lei B, Mace B, Dawson HN, Warner DS, **Laskowitz DT**, James ML. Anti-Inflammatory Effects of Progesterone in Lipopolysaccharide-Stimulated BV-2 Microglia. *PLoS One*, 9(7) 2014. PMID: 25080336

153. Tang X, **Laskowitz DT**, He L, Ostbye T, Bettger JP, Cao Y, Li N, Li J, Zhang Z, Liu J, Yu L, Xu H, Hu Y, Goldstein LB. Neighborhood socioeconomic status and the prevalence of stroke and coronary artery disease in rural China: a population based study 10: 388-95, Int J Stroke. 2015 PMID: 25088683
154. Warner DS, James ML, **Laskowitz DT**, Wijdicks EF. Translational Research in Acute Central Nervous System Injury: Lessons Learned and the Future JAMA Neurol. 71(10):1311-1318 2014 PMID: 25111291
155. **Laskowitz DT**, Kernagis DN. Congenital absence of apolipoprotein E and neurological function JAMA Neurol 71(12): 1578-1579 2014 PMID 25486210
156. Bartels K, Li YJ, Li YW, White WD, **Laskowitz DT**, Kertai MD, Stafford-Smith M, Podgoreanu MV, Newman MF, Mathew JP. Apolipoprotein epsilon 4 genotype is associated with less improvement in cognitive function five years after cardiac surgery: a retrospective cohort study. Can J Anaesth. 62(6):618-626, 2015 PMID: 25744138
157. Lindsey ML, Mayr M, Gomes AV, Delles C, Arrell DK, Murphy AM, Lange RA, Costello CE, Jin YF, **Laskowitz DT**, Sam F, Terzic A, Van Eyk J, Srinivas PR. Transformative Impact of Proteomics on Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association. Circulation, 2015 PMID: 26195497
158. Xie G, Myint PK, Voora D, **Laskowitz DT**, Shi P, Ren F, Wang H, Yang Y, Huo Y, Gao W, Wu YF. Genome-wide association study on progression of carotid artery intima media thickness over 10 years in a Chinese cohort. Atherosclerosis, 243:30-37, 2015
159. Xian Y, Jerome Federspiel J, Grau-Sepulveda M, Hernandez AF, Schwamm LH, Bhatt DL, Smith ES, Reeves MJ, Thomas L, Webb L, Prvu Bettger J, **Laskowitz DT**, Fonarow GC, Peterson ED, “Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator”, JAMA Neurol, 73:50-59,2016 PMID: 26551916
160. Van Wyck DW, Grant GA, **Laskowitz DT**, “Penetrating Brain Injury: A Review of current managements and concepts”, J Neurol Neurphysiol, 2015 (6:6), 1-7
161. Klein RC, Acheson SK, Qadri LH, Dawson AA, Rodriguiz RM, Wetsel WC, Moore SD, **Laskowitz DT**, Dawson HN. “Opposing effects of TBI on excitatory synaptic function in the lateral amygdala in the presence and absence of preinjury stress. J Neurosci Res 2015 PMID: 26707710
162. Berger M, Nadler JW, Friedman A, McDonagh DL, Bennett ER, Cooter M, Qi W, **Laskowitz DT**, Ponnusamy V, Newman MF, Shaw LM, Warner DS, Mathew JP, James ML The effect of propofol versus isoflurane anesthesia on human cerebrospinal fluid markers of Alzheimer’s disease: Results of a Randomized Trial J Alzheimers Dis. 2016 15; 52(4), 1299-1310 PMID: 27079717
163. Wang HB, **Laskowitz DT**, Dodds JA, Xie GQ, Zhang PH, Huang YN, Wang B, Wu YF. Peak systolic velocity measurements with transcranial doppler ultrasound is an independent predictor of incident stroke among general population in China. PLoS One. 2016 Aug 11;11(8):PMID: 27513983

164. Lei B, James ML, Liu J, Zhou G, Venkatramen TN, Lascola CD, Acheson S, Dubois LG, **Laskowitz DT**, Wang H Neuroprotective pentapeptide CN-105 improves functional and histological outcomes in a murine model of intracerebral hemorrhage Scientific Reports 6:34834, 2016 27713572
165. Black RD, Rogers LL, Ade KK, Nicoletto HA, Adkins HD, **Laskowitz DT**. Non-invasive neuromodulation using time varying caloric vestibular stimulation. *IEEE J Transl Eng Health Med*. 2016 PMID: 27777829
166. Guptill JT, Raja S, Ramey S, Boakye-Agyeman F, Noveck R, Tu T-M, **Laskowitz DT**. Phase I, randomized, double-blind, placebo controlled study to determine the safety, tolerability, and pharmacokinetics of a single escalating dose and repeated doses of CN-105 in healthy adult subjects. *J Clinical Pharmacology*, in press, 2016.
- 3a . Books:  
**Translational Research in Traumatic Brain Injury**; **Laskowitz DT**, Grant G (ed) Boca Raton, Fla, CRC Press (Taylor Francis Group), 2016
- 3b. Chapters in books
1. **Laskowitz DT**, Galetta S, Raps E. “Neuro-ophthalmological Emergencies” In Cruz J.(ed): **Neurological and Neurosurgical Emergencies**. Philadelphia, W.B. Saunders, 1998:155-186
  2. Kolson DL, **Laskowitz DT**. “Infectious Emergencies” In Cruz J.(ed): **Neurological and Neurosurgical Emergencies**. Philadelphia, W.B. Saunders, 1998: 89-128
  3. Mahaffey KW, **Laskowitz DT**. “Cardiac manifestations of neurological disorders” In Topel EJ (ed): **Comprehensive Cardiovascular Medicine**. Philadelphia, Lippincott-Raven, 1998: 1005-1017
  4. Mahaffey KW, **Laskowitz DT**. “Cardiac manifestations of neurological disorders” In Topel EJ (ed): **Textbook of Cardiovascular Medicine**. Philadelphia, Lipincott-Raven, 1998: 895-907
  5. **Laskowitz DT**, Borel CO. “Respiratory and bulbar dysfunction in neurological disease” In Miller DH and Raps EC (ed): **Critical Care Neurology**. WB Saunders, Philadelphia, 1999: 1-32
  6. Shiva, S-Y, **Laskowitz DT**, Warner DS. “Pathophysiology of Ischemic Brain Damage”, In Goldstein LB, Shuaib A (ed) **Management of acute stroke**, Marcel Dekker, Inc., New York, 1999:243-278
  7. Kita M, **Laskowitz DT**, Kolson D. “Central nervous system infections” In Miller DH and Raps EC (ed): **Critical Care Neurology**. WB Saunders, Philadelphia, pp 279-330, 1999
  8. Grocott HP, **Laskowitz DT**, Newman MF. “Markers of cerebral injury” In **The Brain and**



- Cardiac Surgery.** Newman S, Harrison M (eds). Harwood Academic Press, London, pp 113-141 1999
9. Mahaffey KW, **Laskowitz DT**. "Neurocardiology" In Topel EJ (ed): **Textbook of Cardiovascular Medicine, Second edition.** Philadelphia, Lipincott-Raven, 2002
  10. **Laskowitz, DT**, Pizzo SV. "Lipoprotein Receptor Signaling" In Henry, HL, Norman AW (eds). **Encyclopedia of Hormones and Related Cell Regulators.** Academic Press, 2003
  11. Dawson HN, **Laskowitz DT**. "Models of Frontotemporal Dementia" In Van Dam D, Peter Paul Van Deyn, (eds) **Animal Models of Dementia.** Humana Press Inc, pp. 533-547, 2011
  12. Dombrowski K, **Laskowitz DT**. "Cardiovascular manifestations of Neurological Disorders" In Biller J (ed): **Handbook of Clinical Neurology,** pp 3-17, 2014
  13. Krishnamurthy K, **Laskowitz DT** "Cellular and molecular mechanisms of secondary neuronal injury following traumatic brain injury" In **Translational Research in Traumatic Brain Injury; Laskowitz DT, Grant G** (ed) Boca Raton, Fla, CRC Press (Taylor Francis Group), 2016
  14. Bennett ER, Reuter-Rice K, **Laskowitz DT** " Genetic influences in traumatic brain injury" In **Translational Research in Traumatic Brain Injury; Laskowitz DT, Grant G** (ed) Boca Raton, Fla, CRC Press (Taylor Francis Group), 2016
  15. Kolls B, **Laskowitz DT**. "Post-traumatic seizures" In **Handbook of Neuroemergency Trials, 2<sup>nd</sup> edition;** Sklonick B, Alves (ed); Elsevier , 2016

Other: a. Published scientific reviews (for mass distribution)

1. Floyd JS, **Laskowitz DT**, "A new approach to the diagnosis of acute ischemic stroke: blood-borne biochemical markers". Stroke Clinical Updates Vol 14; Jan-Feb, 2004.
2. Floyd JS, **Laskowitz DT**. "Biochemical markers in the diagnosis of acute ischemic stroke". The Fats of Life. Volume 17(2), 10-17; 2004

b. Selected abstracts:

1. **Laskowitz DT**, Elion GB, Dewhirst MW, Griffith OW, Friedman HS. "Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion". Proc Annu Meet Am Assoc Cancer Res. 1991.
2. **Laskowitz DT**, Elion GT, Dewhirst MW, Griffith OW, Friedman HS. "Therapeutic interaction between hyperthermia, melphalan, and perturbations of glutathione and

- polyamine levels in human rhabdomyosarcoma xenografts". Proc Annu Meet Am Assoc Cancer Res 1991.
3. Sheng H, **Laskowitz DT**, Bart R, Pearlstein RD, Warner DS. "Isoform specific effects of apolipoprotein E (apoE) on focal ischemia in transgenic mice". Soc Neurosci Abs 23:547, 1997.
  4. **Laskowitz DT**, Sheng H, Bart R, Joyner KA, Roses AD, Warner DS. "Apolipoprotein E deficient mice have increased susceptibility to focal cerebral ischemia". Journal of Cerebral Blood and Metabolism 17: S376, 1997.
  5. Bushnell C, **Laskowitz DT**, Lynch J, Chilikuri V, Borel CO. "Survival, functional outcome, and quality of life following endotracheal intubation for acute stroke". Neurology 50: A413, 1998.
  6. **Laskowitz DT**, McMillian MK, Roses AD. "Apolipoprotein E modulates microglial activation". Neurobiology of Aging 19(Supplement 14): S222, 1998.
  7. Sheng H, **Laskowitz DT**, Pearlstein RD, Warner DS. "Characterization of a recovery global cerebral ischemia model in the mouse". Soc Neurosci Abs, 1998.
  8. Misra U, **Laskowitz D**, McMillian M, Gawdi D, Pizzo S. "APOE3 and APOE4 binding to macrophages triggers inositol (1,4,5-) trisphosphate mediated increases in intracellular calcium". Amer Soc Biochem Mol Biol, FASEB J 12(8), 1998.
  9. Vitek MP, Wright E, Eyster M, **Laskowitz DT**, Sullivan P, Dawson H, Colton CA. "Apolipoprotein E isoform-specific regulation of nitric oxide release". Keystone Abs, 1999.
  10. **Laskowitz DT**, Theksi S, Han SKD, Sheng H, Strittmatter WJ, Vitek M, Schmechel D, Warner DS. "Apolipoprotein E modulates glial activation", American Federation of Aging". Research, 1999.
  11. Pineda JA, Sheng H, **Laskowitz DT**, Pearlstein RD, Crapo J, Warner DS. "Extracellular superoxide dismutase overexpression improves outcome from closed head injury in the mouse". Soc Neurosci Abs:822, 1999.
  12. Gutman CR, Matthew WD, Pizzo SV, **Laskowitz DT**. "Peptides corresponding to the receptor binding region of apolipoprotein E evoke intracellular calcium transients in SK-N-SH neuroblastoma cells". Soc Neurosci Abs:1346, 1999.
  13. Thekde S, Han SKD, Vitek M, Phillips T, **Laskowitz DT**. "Apolipoprotein E modulates glial activation". Soc Neurosci Abs:2007, 1999.
  14. Wellons JC, **Laskowitz DT**, Pearlstein RD, Warner DS, Sheng H. "Comparison of posterior artery patency in C57BL/6J and SV-129 mice: Effect on EEG activity during global cerebral ischemia". Soc Neurosci Abs:315, 1999.

15. Newman MF, Grigore AM, White WD, **Laskowitz DT**, Saunders AM, Grocott HP, Stafford-Smith M, Reves JG. "Apolipoprotein E polymorphism and age of presentation for coronary revascularization". *Anesthesia Analgesia* 88: (4) U89-U89, S APR, 1999.
16. Lynch JR, Pineda J, Morgan D, Warner DS, **Laskowitz DT**. "Apolipoprotein E modulates CNS cytokine expression after head injury". *Society Neuroscience Abstracts*, 127, 2000.
17. Sheng H, Batinic-Haberle I, Crapo JD, Fridovich I, **Laskowitz DT**, Pearlstein RD, Warner DS. "Postischemic intravenous administration of MNTE-2PYP, a metalloporphyrin catalytic anti-oxidant reduces histologic and neurological damage after murine MCAO". *Society Neuroscience Abstracts*, 782, 2000.
18. Pineda JA, Lynch JR, **Laskowitz DT**, Warner DS, Zhang L, Benveniste H. "In vivo microscopy of C57BL/6J and apolipoprotein E deficient mice before and after closed head injury: A 6-week longitudinal study". *Society Neuroscience Abstracts*, 1324, 2000.
19. Gutman CR, Pizzo SV, **Laskowitz DT**, Matthew WD. "ApoE and peptides corresponding to the receptor binding region of apolipoprotein E evoke intracellular signaling via Ca<sup>2+</sup> and PKC". *Society Neuroscience Abstracts*, 1792, 2000.
20. Parra A, Sheng H, Pearlstein RD, **Laskowitz DT**, Warner DS. "Delayed transient arteriopathy after subarachnoid hemorrhage in mice: external vascular diameter measure versus histological quantitative technique". *Society Neuroscience Abstracts*, 1812, 2000.
21. Wellons JC, Sheng H, **Laskowitz DT**, Pearlstein RD, Warner DS. "Strain-Related Differences in Recovery Models of Murine Transient Forebrain Ischemia: Anatomy, Histology, EEG, and Regional Cerebral Blood Flow". *American Association of Neurological Surgeons*, 2000.
22. Stanley TO, Grocott HP, Phillips-Bute B, **Laskowitz D**, Hilton AK, Mathew JP, Debruijn N, Newman MF. "Aortic atheroma and the risk of stroke and encephalopathy after cardiac surgery". *Anesthesia Analgesia (Supplement)* 90(4):SCA38, 2000.
24. Laskowitz DT, Morgan D, Mance J, Matthew WD, **Lynch JR**. "Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response". *American Federation of Aging Research*, 2000.
25. Wellons JC, Sheng H, Pineda J, Masey G, Pearlstein RD, Warner, DS, **Laskowitz DT**. "Intra-cerebroventricular infusion of human recombinant apolipoprotein E3 reduces global ischemic brain injury in apolipoprotein E deficient mice". *Neurosurgery* 47:532, 2000.
26. Grocott HP, **Laskowitz DT**, El-Moalem H, Bainbridge D, Butler A, Newman MF: "APOE genotype differentially influences the pro and anti-inflammatory response to cardiopulmonary bypass". *Society of Cardiovascular Anesthesiology*, 2001.
27. Kim, JW, Pineda J, Lynch J, **Laskowitz DT**, Warner DS, Benveniste H. "High resolution MRI of stereotactically induced closed head injury in mice". *American Association of Neurological Surgeons*, 2001.

28. Grocott, HP, **Laskowitz, DT**, El-Moalem, H, Reves JG, Newman MF. "B-type natriuretic peptide and intensive care length following CABG". American Society of Anesthesiology, 2001.
29. Parra A, McGirt M, Sheng H, Pearlstein RD, **Laskowitz, DT**, Warner DS. "Effects of extracellular superoxide dismutase on arterial vascular structural changes after acute subarachnoid hemorrhage in the mouse". Stroke 32(1): 359, 2001.
30. Sato Y, **Laskowitz DT**, Bennett ER, Grocott, HP. "Does Cardiopulmonary Bypass Induce Cerebral Apoptosis in the Rat?", American Society of Anesthesiology, 2001.
31. Lynch JR, Leinweber S, Pineda J, Warner DS, **Laskowitz DT**, "Apolipoprotein E mimetic peptide is protective in a murine head injury model". Soc Neuroscience Abstracts, 2001.
32. Aono M, Kim KS, Massey GW, Bennett ER, **Laskowitz DT**, Pearlstein RD, Warner DS. "Protective effect of peptides corresponding to the receptor binding region of apoE on NMDA excitotoxicity in primary neuronal-glia cultures". Soc Neuroscience Abstracts, 2001.
33. Parra A, McGirt MJ, Sheng H, Pearlstein RD, **Laskowitz DT**, Warner DS. "Delayed transient arteriopathy after subarachnoid hemorrhage in the mouse: external vascular measurement versus histological technique". Soc Neuroscience Abstracts, 2001.
34. McGirt MJ, Parra A, Higuchi Y, Sheng H, **Laskowitz D**, Pearlstein RD, Warner DS. "Attenuation of Cerebral Vasospasm after Subarachnoid Hemorrhage in Mice Overexpressing Extracellular Superoxide Dismutase". Stroke 33 (1): P103, 2002.
35. McGirt MJ, Lynch J, Sheng H, **Laskowitz D**, Pearlstein RD, Warner DS. "Simvastatin Induced Up-regulation of Endothelial Nitric Oxide Synthase Ameliorates Cerebral Vasospasm Following Subarachnoid Hemorrhage". Neurosurgery 51 (2): 815 AUG 2002.
36. McGirt MJ, Lynch J, Parra A, Blessing B, Borel C, Warner D, **Laskowitz DT**. "Serum von Willebrand Factor, Matrix Metalloproteinase-9, and Vascular Endothelial Growth Factor Effectively Predicts the Development of Cerebral Vasospasm after Aneurysmal Subarachnoid Hemorrhage". Southern Society of Neurological Surgeons, 2002.
37. McGirt MJ, Lynch J, Parra A, Blessing B, Borel C, Warner D, **Laskowitz D**. "Serum Markers of Neointimal Proliferation Effectively Predict the Onset of Cerebral Vasospasm after Aneurysmal Subarachnoid Hemorrhage". Neurosurgery 51 (2): 712 A.
38. McGirt MJ, Bulsara K, Lynch JR, **Laskowitz DT**, Friedman, AH. "Troponin Trend Differentiates Myocardial Infarction from Reversible Neurogenic Cardiac Ventricular Dysfunction Following SAH". Stroke 33 (1): P94, 2002.
39. Lynch JR, McGirt MJ, Warner DS, **Laskowitz DT**. "A novel Panel of Serum Markers Predict Vasospasm after subarachnoid hemorrhage". Keystone Abs, 2002.
40. McGirt MJ, Parra A, Sheng H, **Laskowitz DT**, Pearlstein RD, Warner DS. "Oxidative stress contributes to the development of cerebral vasospasm following subarachnoid

hemorrhage”. American Heart Association, Feb 2002

41. McGirt MJ, Lynch JR, Sheng H, **Laskowitz DT**, Pearlstein RD, Warner DS. “The role of HMG CoA Reductase inhibitors in the prophylaxis of cerebral vasospasm after subarachnoid hemorrhage”, *Keystone Abs*, 2002.
42. McGirt MJ, Blessing B, Lynch JR, Bulsara KR, **Laskowitz DT**. “Positive predictive value of transcranial Doppler for the diagnosis and outcome of patients with subarachnoid hemorrhage”. American Association of Neurological Surgeons, 2002.
43. Lynch JR, McGirt MJ, Warner DS, **Laskowitz DT**. “Simvastatin, an HMG CoA Reductase Inhibitor, Increases Endothelial Nitric Oxide Synthase and Attenuates Cerebral Vasospasm following subarachnoid hemorrhage in mice”. *Neurology* 58: A367-A367 Suppl. 3: 9 2002.
44. McGirt MJ, Lynch JR, Sheng H, **Laskowitz DT**, Pearlstein RD, Warner DS. “The role of HMG CoA Reductase inhibitors in the prophylaxis of cerebral vasospasm after subarachnoid hemorrhage”, *Keystone Abs*, 2002.
45. McGirt MJ, Blessing B, Lynch JR, Bulsara KR, **Laskowitz DT**. “Positive predictive value of transcranial Doppler for the diagnosis and outcome of patients with subarachnoid hemorrhage”. American Association of Neurological Surgeons, 2002.
46. Lynch JR, McGirt MJ, Warner DS, **Laskowitz DT**. “Simvastatin, an HMG CoA Reductase Inhibitor, Increases Endothelial Nitric Oxide Synthase and Attenuates Cerebral Vasospasm following subarachnoid hemorrhage in mice”. *Neurology* 58: A367-A367 Suppl. 3: 9 2002.
47. Matthew JP, Grocott HP, Phillips-Bute B, Stafford-Smith M, **Laskowitz DT**, Rossignol D, Newman MF. “Lower endotoxin immunity predicts increased cognitive dysfunction in the elderly after cardiac surgery”. *Anesthesia Analgesia* 93:SCA27, 2002.
48. McCurdy JR, Knauth K, Grocott HP, **Laskowitz DT**, Ti LK, Lynch JR, White WD, Stafford M, Newman MF, Matthew JP. “Statin therapy does not decrease neurocognitive deficit after cardiopulmonary bypass”. *Anesthesia Analgesia*, 93:SCA29, 2002.
49. **Laskowitz, DT**, Lynch JR. Warner DS, Pineda J. “Apolipoprotein E modulates the CNS response to injury”. *J Neurochem* 81; Supp 1:31, 2002.
50. Leinenweber SB, Sheng HX, Lynch J, Sheng H, **Laskowitz DT**, Warner DS. “Effects of a Lieinenweber S, Wang H, Laskowitz DT, Warner D,. “Metallopporphoryn catalytic antioxidant in a murine model of closed head injury”. *Pediatr Res* 51(4): 276 Part 2 Suppl, 2002.
51. McGirt MJ, Lynch J, Nimjee S, **Laskowitz DT**. “Elevation in serum brain natriuretic peptide correlates with cerebral vasospasm and hyponatremia after subarachnoid hemorrhage”. Annual Meeting of the Congress of Neurological Surgeons, October, 2003.

52. McGirt MJ, Lynch J, Pearlstein RD, Warner DS, **Laskowitz DT**. "Simvastatin and lovastatin improve neurological outcome and attenuate hippocampal degeneration after closed head injury in the mouse". Annual Meeting of the Congress of Neurological Surgeons, October, 2003.
53. Wang H, Tan W, Vitek MP, Bennett ER, Sullivan P, Warner DS, **Laskowitz DT**, Lynch, JR. "APOE Genotype and a Small Apoe Related Peptide Modify The Systemic and the CNS Inflammatory Response". Annual Meeting of the Society for Neuroscience, November 2003.
54. Floyd, J, Lynch JR, Wang H, Warner DS, Blessing R, **Laskowitz DT**. "A panel of biomarkers accurately predicts vasospasm after subarachnoid hemorrhage". Annual Meeting of the Congress of Neurological Surgeons, October, 2003.
55. McGirt MJ, Lynch JR, Pearlstein RD, Warner DS, **Laskowitz DT**. "Statins improve neurological outcome, attenuate hippocampal neuronal degeneration, and decreased interleukin-6 production after experimental traumatic brain injury". *Neurosurgery* 53(2): 481, 2003.
56. Floyd J, Blessing R, White W, Lynch JR, **Laskowitz DT**. "A Panel of Biomarkers Accurately Predicts the Diagnosis of Acute Ischemic Stroke". American Heart Association International Stroke Conference, February, 2004.
57. Lynch JR, Wang H, Tang W, Vitek M, Durham L, Sullivan P, Warner DS, **Laskowitz DT**. "ApoE-based therapeutic improves outcome and reduces Alzheimer's Disease pathology after head injury." *Annals of Neurology* 56: S42, Toronto Canada, 2004.
58. McGirt M, Pradilla, G, Lynch, JR, Legnani, FG, Perez, M, Tamargo, R, Clatterbuck, RE, **Laskowitz, DT**. "Simvastatin Attenuates Experimental Cerebral Vasospasm and Ameliorates Serum Markers of Neuronal Injury in Patients after Subarachnoid Hemorrhage: A Dose-response Effect Dependent on Endothelial Nitric Oxide Synthase". *CNS*, October 2004.
59. Wang H, Durham L, Tang W, Warner DS, Bennett ER, Vitek MS, **Laskowitz DT**, Lynch JR. "An apoE mimetic improves outcome after brain injury". Society for Neuroscience, Oct, 2004.
60. **Laskowitz, DT**. "ApoE and Alzheimer's disease". Society for Neuroscience, Oct 2004.
61. McAdoo JD, Warner DS, Pearlstein R, Gross RF, Goldberg RN, **Laskowitz DT**. "Apolipoprotein E-mimetic peptide reduces brain injury in a neonatal hypoxia-ischemia model". *Pediatric Research* 55(4): 2320, 2004.
62. Ionita C., Zaidat O., **Laskowitz DT**, Lynch JR, Chilikuri V, Alexander MF, Friedman AH., Graffagnino, C. "The value of adding CT angiography to Transcranial Doppler sonography in triaging patients with subarachnoid hemorrhage and suspected vasospasm prior to conventional angiogram". Society for Neurocritical Care, 2005.
63. Ionita C., Zaidat O., Alexander MF, Friedman AH., **Laskowitz DT**, Lynch JR, Chilikuri V, Borel C, Graffagnino C. "Effect of treatment modality of ruptured intracranial aneurysm on the incidence of vasospasm and mortality". Society for Neurocritical Care, 2005.
64. Ionita CC, Zaidat O, Floyd J, Alexander MJ, Friedman A, Lynch JR, **Laskowitz D**, Chilukuri VR,

- Graffagnino C. "Incidence of vasospasm in aneurysmal subarachnoid hemorrhage; Surgical clipping versus endovascular coiling". American Academy of Neurology Miami, FL; Neurology 64(6) A405, 2005.
65. Lynch JR, McGirt MJ, Floyd J, Blessing R, **Laskowitz DT**. "Simvastatin attenuates serum markers of vasospasm after aneurysmal subarachnoid hemorrhage". American Heart Association International Stroke Conference, New Orleans, 2005.
  66. Girard, TD; Jackson JC; Pun, BT; Ely, EW. Renfrew JW; Dunn. J; **Laskowitz, DT**. "Apolipoprotein E4 polymorphism as a genetic predisposition to delirium in humans". Society of Critical Care Medicine, San Francisco, CA. SA22, 2005.
  67. Lynch JR, Jauch E, Floyd J., Blessing R., **Laskowitz DT**. "A panel of serum markers accurately diagnoses acute stroke". American Heart Association International Stroke Conference, New Orleans, 2005.
  68. Li, F, McKenna SE, **Laskowitz DT**, Colton CA, Vitek, MP. "ApoE mimetic peptides reduce myelin oligodendrocytes glycoprotein-induced experimental autoimmune encephalomyelitis in mice". Society for Neuroscience, Washington DC, 2005.
  69. Ohkubo N, Toku K, **Laskowitz DT**, Colton CA, Vitek MP. "Signaling cascade for apoE-peptide-mediated inhibition of inflammation". Society for Neuroscience, Washington DC, 2005.
  70. Takata K, Borel CO, Lombard FW, **Laskowitz DT**, Warner DS. "A rat model of cerebral vasospasm resulting in chronic motor and neurocognitive deficits following experimental SAH". Society of Neurosurgical Anesthesia and Critical Care, Chicago, IL, 2006.
  71. Stanley L, **Laskowitz DT**, Cairns CB. "Pediatric patients are less likely to be eligible and to consent to participate than adult patients in an acute brain injury study". Ann Emer Med, 50 (3):S47-48, Society for Academic Emergency Medicine, Chicago, 2007.
  72. Blake C, Wang H, Nimjee SM, **Laskowitz DT**, Sullenger A. "Antidote reversal of a novel anticoagulant decreases mortality and improves neurological function in a murine model of subarachnoid hemorrhage". International Society on Thrombosis and Haemostasis, Geneva, Switzerland, 2007.
  73. Ivancevich N, Nicoletto H, Scism M, Bennett E, **Laskowitz DT**, S. W. Smith. "Real-Time 3D Contrast-Enhanced Transcranial Ultrasound". IEEE International Ultrasonics Symposium, Vancouver, Canada, 2007.
  74. Takata K, Sheng H, Borel CO, **Laskowitz DT**, Warner DS, Lombard FW. "Simvastatin reduces Cognitive Dysfunction following Subarachnoid Hemorrhage in the Rat". Society for Neurosurgical Anesthesiology and Critical Care, San Francisco, CA 2007.
  75. Stoner CV, Lassiter TF, **Laskowitz DT**. "Phenytoin vs. Levetiracetam: A Cost Analysis in a Neurocritical Care Unit". American Epilepsy Society, Philadelphia, PA, 2007.
  76. James, ML, Wang H, Warner DS, **Laskowitz DT**. "Apolipoprotein E genotype influences outcome in a murine model of collagenase-induced intracranial hemorrhage". Society for Neurosurgical

Anesthesiology and Critical Care, San Francisco, CA 2007.

77. Wang H, Warner DS, Sheng H, Vitek MP, **Laskowitz DT**. “An ApoE-mimetic Peptide improves outcome after transient focal ischemia in mice”. American Society of Anesthesiologists, San Francisco, 2007.
78. Chandra A, **Laskowitz D**, Cairns CB. “Pediatric patients are less likely to be eligible and to consent to participate than adult patients in an acute brain injury study”. *Ann Emerg Med* 2007, American College of Emergency Physicians Research Forum, Seattle, WA, 2007.
79. James ML, Blessing R, **Laskowitz DT**. “APOE polymorphism affects cerebral edema but not hematoma size after intracerebral hemorrhage in humans”. Society for Neurocritical Care, Las Vegas, NV, 2007.
80. Stanley L, Chung M, Scism M, Cairns C, Olson D, **Laskowitz DT**. “A panel of biomarkers accurately predicts intracranial pathology”. Society for Neurocritical Care, Las Vegas, NV, 2007.
81. Stoner CV, Lassiter TF, **Laskowitz DT**. “Phenytoin vs. Levetiracetam: A Cost Analysis in a Neurocritical Care Unit”, American Epilepsy Society, Philadelphia, *Epilepsia* 48:319, 2007.
82. James ML, Wang H, **Laskowitz DT**, “Human APOE genotype confers neuroprotection in a murine model of intracranial hemorrhage”. Society for Neurocritical Care, Las Vegas, NV, 2007
83. **Laskowitz DT**, Nocoletto HA, Ivancevich NM, Ointong G, Snith SW. Real Time 3D Contrast-Enhanced Transcranial Ultrasound: Development of a New Technology”. *Stroke* 39(2), 578, 2008, International Stroke Conference, New Orleans, LA.
84. James ML, Wang H, **Laskowitz DT**. “Effect of human APOE genotype on a murine model of intracerebral hemorrhage”. *J Neuroanesthesiol* 10(4):291-352, 2007.
85. James ML, **Laskowitz DT**. “ApoE polymorphism affects cerebral edema but not hematoma size after intracerebral hemorrhage in humans”. Society for Neurocritical Care, Las Vegas, NV, 2007.
86. Phillips S, Glickman SW, Stanley L, Kim ET, **Laskowitz DT**, Cairns CB. “A novel biomarker panel distinguishes stroke from mimics in the Emergency Department”. Society for Academic Emergency Medicine, 2008.
87. Blake CM, Wang H, Sullenger BA, **Laskowitz DT**. “Factor IXa aptamer and antidote improve outcomes following murine MCAO and SAH”. International Stroke Conference, New Orleans, 2008.
88. Phillips S, Glickman SW, Stanley L, Kim ET, **Laskowitz DT**, Cairns CB. “Initial D-Dimer levels predict severity in ED patients with stroke”. Society for Academic Emergency Medicine, 2008.
89. Phillips S, Glickman SW, Stanley L, Preston R, Grant G, **Laskowitz DT**, Cairns CB. “C-Reactive Protein as a Serum Biomarker in the Evaluation of Patients with Minor Head Injury and Normal Mental Status in the Emergency Department”. *Ann Emerg Med*, 52(4):S124, 2008, American College of Emergency Physicians Research Forum.
90. Song P, Wang H, Vitek MP, Sullivan PM, **Laskowitz DT**. “A novel apoE mimetic therapeutic



- reduces AD pathology in a double transgenic murine model”. Society for Neuroscience, 2008.
91. Nouh A, Blessing R, **Laskowitz DT**, Bennett ER, James ML. “S100 $\beta$  and BNP Predict Functional Outcome after Intracerebral Hemorrhage”. Society for Neurocritical Care, 2008.
  92. James ML, Wang H, Song PP, **Laskowitz DT**. “Brain natriuretic peptide improves functional outcome after acute brain injury in mice”. Crit Care Med 37 (12): A16, 2009, Society for Critical Care Medicine.
  93. Lindsey BD, Ivancevich NM, Ligh ED, Smith SW, Nicoletto EA, Bennet ER, **Laskowitz. DT**. “The ultrasound brain helmet for 3D transcranial Doppler imaging”. IEEE International Ultrasonics Symposium, Rome, Italy, 2009.
  94. Grant G, Bennett ER, **Laskowitz DT**, A Panel of Biomarkers accurately predicts the probability of intracranial pathology in mild traumatic brain injuries” Military Health Research Form (DOD) Kansas City, MO Aug, 2009
  95. Hussein N, **Laskowitz DT**, Guidon A, Olson, DM, Pan W, Zimmer, LO, Peterson ED, Goldstein LB, Bushnell CD. “Factors associated with post-stroke antidepressant use: data from the AVAIL registry”. Presented at the American Heart Association Quality of Care and Outcomes Research (QCOR) Symposium, 2010.
  96. James ML, Wang H, Cantillana V, Kernagis D, Dawson HN, **Laskowitz DT**. “Microglial-specific inhibition improves function after acute brain injury. Society for Neurocritical Care, San Francisco, 2010.
  97. Lindsey BD, Light ED, Snith SW, Nicoletto HA, Bennett ER, **Laskowitz DT**. “Dual matrix arrays integrated into scanner for increased SNR of ultrasound brain helmet”. IEEE International Ultrasonics Symposium, San Diego, CA, 2010.
  98. Wang H, Lei B, Lyuboslavsky P, Wilson L, James ML, Lascola CD, **Laskowitz DT**. “pH sensitive NMDA inhibitor improves outcome in a murine model of SAH”. Society for Neuroscience, San Diego, 2010.
  99. El-Husseini N, Goldstein LB, Olson D, Pan W, Zimmer, L, Peterson E, **Laskowitz DT**, Bushnell, CD. “Depression and the use of antidepressants after stroke and TIA: an opportunity for drug treatment”. AHA Quality Care and Outcome Research, Washington, DC, 2010.
  100. McDonagh,DL, Mathew JP, **Laskowitz DT**, Phillips-Bute, B, Newman MF. “Biomarkers of Brain Injury and Postoperative Cognitive Dysfunction after Major Noncardiac Surgery”. American Society Anesthesiology, Chicago, IL, 2011.
  101. James ML, **Laskowitz D**, McDonagh D, Sun W. “Leukocytosis as a Predictor of Neurological Deterioration after Intracerebral Hemorrhage”. American Society Anesthesiology, Chicago, IL, 2011.
  102. Smoak K, Madenspacher J, Gong W, **Laskowitz D**, Vitek M, Remaley A, Wang J, Fessler M. “Apolipoproteins and apolipoprotein peptidomimetics modulate airway Inflammation through suppressive effects on chemokine-directed leukocyte migration”. Am J Respir Crit Care Med 183:2011:A2787, American Thoracic Society, Colorado, 2011.

103. Smith S, **Laskowitz DT**, Bennett E. “Nicoletto H, System for fused 3D visualization of cerebral arterial flow”. IEEE International Ultrasonics Symposium, Orlando, FL, 2011.
104. Guptill, J, Granger C, Armstrong P, Pieper C, Horton J, **Laskowitz, DT**, Lopes R. “Most Strokes Occur More Than 48 Hours Following Primary Percutaneous Coronary Intervention in STEMI: the Stroke Experience in APEX-AMI Trial”. American Heart Association International Stroke Conference, Orlando, FL, 2012.
105. Kashani K, Hanson L, **Laskowitz, DT**, Wagner L, Ilhan , Lieske L, “Novel biomarkers of AKI: multicenter prospective cohort study”. American Society of Nephrology, Philadelphia, PA, 2011.
106. Terrell T., Bostick R., Barth J., McKeag D., Cantu R., Bennett E., Xie D., **Laskowitz D.**, Sloane R., Wortley M., Bielak K., Abramson R., Castle R. “ Prospective cohort study of associations of APOE, APOE promoter G-219T, and Tau genotypes with concussion in athletes”. Clin J Sports Med 21, pp 160, 2011, Society for Sports Medicine, Salt Lake City, UT.
107. Terrell T.R., Bostick R., Barth J., Cantu R., Sloane R., McKeag D., Erlanger D., **Laskowitz D.**, Abramson R. “Relationship between prior concussion history and baseline headminder neuropsychological test results in an intercollegiate student athlete population”. Clin J Sports Med 21:4, pp 376-377, 2011, Canadian Academy of Sport and Exercise Medicine Canadian Sport Medicine Conference. St. John's, NL Canada.
108. Terrell, TR, Bostick R, Barth J, McKeag D, Cantu CR, Bennett ER, **Laskowitz DT**, Bielak K, Asif I, Nobles, TJ, Rader B, Yeager J, Petron D, Prospective cohort study of the association of genetic polymorphisms and concussion risk and postconcussion neurocognitive deficits in college athletes, American Society for Sports Medicine, 21<sup>st</sup> Annual Meeting, Atlanta, GA, 2012
109. Hussein N, Goldstein LB, Peterson ED, Zhao X, Oan W, Olson D, Zimmer LO, Williams JW, Bushnell C, **Laskowitz DT**. “The impact of depression on post-stroke functional recovery”. American Heart Association International Stroke Conference, Orlando, FL, 2012.
110. McFarlin JM, Emery C, Gray M, Sun W, Philips-Bute, B, **Laskowitz D**, McDonagh D, James ML, “Patient characteristics that correlate with a new, early, do not resuscitate order in intracerebral hemorrhage”, Neurocritical Care 17:S145, Society Neurocritical Care, Denver CO, 2012
111. Sharma R, **Laskowitz DT** “Blood-Based Biomarkers Detect Acute Ischemic and Hemorrhagic Strokes” American Heart Association International Stroke Conference, Honolulu, HI, 2013.
112. El Hussein N, **Laskowitz DT**, Bennett ER, Li Y, Williamson R, Hailey C, Richardson K, and Michael James, “SNP rs10940495 in the Gp-130 Locus Is Associated with Functional Outcome Following Spontaneous Intracerebral Hemorrhage”, American Academy of Neurology, San Francisco, CA, 2013
113. Juan H, **Laskowitz DT**, Peterson E, Xian Y “Prior Warfarin Treatment and Intracranial Hemorrhage among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator: A Meta-analysis”, AHA Quality Care and Outcome Research, Baltimore MD, 2013.

114. Yu, A, Wang H, **Laskowitz DT**, Bass D A “Novel Mouse Model of Blast Brain Injury: Blast Conditions Seen in Theater” Biomedical Engineering Society, Seattle, WA 2013
115. Gokhale S, Wang H, Zhou H, **Laskowitz DT**, Novel pH-sensitive NMDA antagonist improves functional recovery and reduces vasospasm in a murine model of subarachnoid hemorrhage” Neurocrit Care S16, Society Neurocritical Care, Philadelphia, PA, 2013
116. Gaoqiang X, **Laskowitz DT**, Turner EL, Egger J, Ying L, Zhao L, Shi P, Ren F, Wu Y Baseline quality of life and all-cause mortality in 10-year follow-up in a Chinese population-based cohort”, World Congress of Cardiology Scientific Sessions, Melbourne Australia, 2014
117. Fitzpatrick J, Laskowitz DT, Lascola C. Inhibition Of Quinone Oxidoreductase 2 Improves Learning In A Mouse Model Of Vascular Dementia” American Academy of Neurology Annual Meeting, Philadelphia, PA, 2014
118. Gokhale S, Kernagis D, Lei B, Li Y, **Laskowitz DT**, James ML, “Sex specific differential gene expression in a murine model of experimental intracerebral hemorrhage”, American Heart Association International Stroke Conference, San Diego CA, Feb 2014
119. Wang H, Venkatraman TN, Fang C, Tan Y, Lascola CD, **Laskowitz DT**, Functional and Imaging Studies of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-350 in a Clinically Relevant Murine Model of Closed Head Injury (CHI) , American Academy of Neurology, Vancouver, 2016
120. Kurtzberg J, Durham R, Bennett ER, Balber A, **Laskowitz DT**. Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke (CoBIS), American Society for Blood and Marrow Transplantation, Hawaii, 2016
121. Black R, **Laskowitz DT**. “Non-invasive neuromodulation using time-varying caloric vestibular stimulation”, American Academy of Neurology, Vancouver, 2016
122. Rosenberg A, Dawson H, Wang H, **Laskowitz DT**. Assessing the Therapeutic Potential of Epoprostenol D and an ApoE mimetic peptide in a Murine Model of Chronic Traumatic Encephalopathy American Academy of Neurology, Vancouver, 2016
123. Zaczek R, Myers SJ, **Laskowitz DT**, Ruppia KB, Menaldino DS, Dentmon Z, Lyuboslavsky, P, Koszalka GW. “NP10679: A pH Sensitive GluN2B Inhibitor to Improve Outcomes Post Subarachnoid Hemorrhage by Preventing Ischemic Neuronal Damage”, American Society for Experimental Neurotherapeutics, Bethesda, 2016
124. Marrotte, E, **Laskowitz DT**. Central Nervous System Extracellular Matrix Inhibition of Endothelial Progenitor Cell Adhesion and Proliferation Can be Ameliorated with the Use of a Novel Poly(Ethylene Glycol) Hydrogel, 14<sup>th</sup> Annual Society Neurocritical Care, National Harbor, MD, 2016
125. Kurtzberg J, Troy J, **Laskowitz D**, Bennett E, Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke. American Society of Hematology, Houston, 2016

c. Editorials, position, and background papers.

1. Crino PB, Zimmerman R, **Laskowitz DT**, Raps EC, Rostami AM. “Magnetic resonance imaging of the cauda equina in Guillan-Barre Syndrome”. *Neurology* 45(5):1024-1027, 1995.
2. Floyd JS, **Laskowitz DT**. “A new approach to the diagnosis of acute ischemic stroke: blood-borne biochemical markers”. *Stroke Clinical Updates* (a publication of the National Stroke Association), Vol 14; Jan-Feb, 2004.
3. Lynch JR, **Laskowitz DT**. “A panel of serum markers for rapid diagnosis of stroke”. *Stroke*, Apr, 2004.
4. Warner DS, **Laskowitz DT**. “Changing Outcome from Aneurysmal Subarachnoid Hemorrhage: Another step closer”. *Anesthesiology*. 104(4): 629-630, 2006.

**Patents:**

United States Patent 9,303,063, April 5, 2016  
 Peptide Compounds for suppressing inflammation  
 Inventors: **Laskowitz DT**, Dawson HN, Kolls, B

United States Patent 9,018,169, April 28, 2015  
 International Filing Date: March 16, 2012  
 Peptides for suppressing inflammation  
 Inventors: **Laskowitz DT**, Dawson HN, Kolls, B

United States Patent 8,228,336. October 16, 2012  
 Treatment of subarachnoid hemorrhage with apoE analog.  
 Inventors: Vitek MP, **Laskowitz DT**

United States Patent 8,198,234B2. June 12, 2012  
 Methods of suppressing microglial activation.  
 Inventors: **Laskowitz DT**, Matthew WD, McMillian M

United States Patent 8,093,209. January 10, 2012  
 Methods of suppressing microglial activation and systemic inflammatory responses.  
 Inventors: **Laskowitz DT**, Matthew WD, McMillian M

United States Patent 8,034,762. October 11, 2011  
 Treatment of subarachnoid hemorrhage with apoE analog.  
 Inventors: Vitek MP, **Laskowitz DT**

United States Patent 7,915,226. March 29, 2011

Methods and compositions of suppressing the activation of microglial cells in the central nervous system.

Inventors: **Laskowitz DT**, Matthew WD, McMillian M

United States Patent 7,592,141. September 22, 2009

Methods of identifying individuals at reduced risk of sepsis.

Inventors: Schwinn DA, **Laskowitz DT**, Podgoreanu MV, Moretti EW

United States Patent 7,319,092. January 15, 2008

Methods of suppressing microglial activation.

Inventors: **Laskowitz DT**, Matthew WD, McMillian M

United States Patent 7,205,280 April 17, 2007

Methods of ameliorating or treating the neurological effects of cerebral ischemia or inflammation.

Inventors: **Laskowitz DT**, Matthew WD, McMillian M

Consultant appointments: (Include US government, state, private organizations, etc.)

Consultant	Astute Biomedical, San Diego, CA
Consultant	NeurOp Pharma, Atlanta, GA
Ad hoc Reviewer	Merit Review Grants, Dept. of Veterans Affairs
Ad hoc Reviewer	Neurobiology of Aging
Ad hoc Reviewer	Stroke
Ad hoc Reviewer	Neuroscience Journal
Ad hoc Reviewer	Cerebral Blood Flow and Metabolism
Ad hoc Reviewer	Annals of Neurology
Ad hoc Reviewer	Stroke
Ad hoc Reviewer	Critical Care Medicine
Ad hoc Reviewer	Neuroscience
Ad hoc Reviewer	Anesthesia Analgesia
Ad hoc Reviewer	Neurocritical Care
Ad hoc Reviewer	Neurobiology of Disease
Ad hoc Reviewer	Clinical Chemistry
Ad hoc Reviewer	Neurology
Ad hoc Reviewer	Journal of Cerebral Blood Flow and Metabolism
Ad hoc Reviewer	American Journal of Medicine

Professional awards and special recognitions:

1987	A.A. Bennet Award in Neuroscience
1987	Sc.B., Magna cum laude, Honors in Neuroscience (Brown University)

1991	Sandoz Award for Superior Academic Achievement
1992	Long Island Jewish Medical Center Intern of the Year
1995	American Association of Neurology Resident Scholar Award
1997	Best Laboratory-Based Research, DUMC Dept. of Anesthesiology
1997	National Stroke Association Fellowship
1997	Genentech Young Investigator Award in Stroke
1997	Upjohn and Pharmacia Award for Outstanding CNS Research
1999	Paul Beeson Physician Faculty Scholar
2001	Fellow, American Heart Association
2003	Fellow, American Neurological Association
2010	2010 Annual Scientific Award, Society of Critical Care Medicine
2011	Faculty inductee, AOA Medical Honor Society

National Organizations and participation: (Offices held, committee assignments, etc.)

1992-present	American Academy of Neurology
1998-present	Fellow, American Heart Association Stroke Council
1998-present	Society for Neuroscience
2000	Study section; American Heart Association
2002-present	American Society of Neuroimaging
2003 present	Neurocritical Care Society (Charter member)
2003-present	Fellow, American Neurological Association
2004-present	Grant Review Committee, Toronto Sick Kids Foundation
2005-Present	Grant Review, Committee, Israel Science Foundation; Center for Integrative Medicine

Teaching responsibilities including continuing education:

Medical Student Education:

Chair, SOM 3<sup>rd</sup> Year Medical Student Education Committee  
 Medical student CPC: Management of Traumatic Brain Injury  
 Clerkship Lecture Series: Neurological Emergencies  
 Introduction to the Neurological Examination

Housestaff (Residency and Fellowship) Education:

Resident Preceptor  
 Emergency Neurology Series  
 “Emergent management of Traumatic Brain Injury”  
 “Emergency management of intracranial and subarachnoid hemorrhage”  
 “Neurovascular ultrasound: technique and practical applications”

Morning Resident Report

Stroke Conference

Neuroscience Lecture Series

“Ventilatory management in the Neurointensive Care Unit”  
 “Diagnosis and Management of Subarachnoid hemorrhage”

“Herniation syndromes and neurological evaluation of the comatose patient”  
 “CSF dynamics and evaluation in neurological disease”  
 “Acute blood pressure management for Neurocritical Care Diseases”  
 Attending Rounds, Neurosciences Critical Care Unit, Inpatient Neurology

**Invited Lectures/Continuing Medical Education:**

- 11/16 :Neuroscience Medicine: Focus on Translation”, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC
- 6/16 “Translational research in stroke: from bench to bedside”, University of Kentucky, Lexington, KY
- 10/15 “Incorporating translational research into the medical school curriculum”, Duke-NUS, Singapore
- 10/15 “ApoE: from gene to therapy”, DCRI Neurosciences Symposium sponsored by NC Biotechnology Center”, Raleigh, NC
- 8/15 “Translational Neuroscience”, UCB Pharma, Duke University School of Medicine, Durham, NC
- 4/15 “The current status and promise of biomarkers in stroke”, Medical World Americas, Houston, TX
- 2/15 “Blood Based Biomarkers in the Diagnosis of stroke”, International Stroke Conference, Nashville, TN
- 1/15 “Early secondary stroke prevention as an acute therapeutic intervention” SOCRATES National Investigator Meeting, Duke Clinical Research Institute, Durham, NC 27710
- 1/15 “Anatomic Localization of Disconnection Syndromes in Clinical Neuropsychology”. Duke University, Durham, NC 27710
- 10/14 “Field Biomarkers of Stroke”, NINDS/Brain Attack Coalition, Bethesda, MD
- 6/14 “International Training in Clinical Research Methodology for Cerebrovascular Disease research”, Tiantan Stroke Conference, Beijing, China
- 6/14 “New perspectives in intracranial hemorrhage: an international and translational perspective”, Tianjin Neurological Institute, Tianjin, China
- 5/14 “Translational research in stroke: moving from mechanisms to Therapeutics:”, Dean Interdisciplinary Colloquium on Neuroplasticity and Post-Stroke Recovery; Duke University School of Medicine, Durham, NC

- 4/14 “Biomarkers of CNS injury following mild TBI”, Dean’s Interdisciplinary Colloquium on Traumatic Brain Injury and Concussion ; Duke University School of Medicine, Durham, NC 27710
- 2/14 “Utility of Biomarkers in the Pre-hospital Diagnosis of Stroke”, Stroke Belt Consortium, Orlando, Fla
- 10/13 “Academic Medicine and Translational Neuroscience”, Distinguished Overseas Speaker Seminar, Duke-NUS, Singapore
- 10/13 “Career Development: Translational Research”, American Neurological Association, New Orleans, LA
- 9/13 “Stroke: Pathophysiology, Diagnosis, Treatment, and Research Opportunities, Duke Clinical Research Institute, Durham, NC
- 8/13 “Department of Neurology at Duke: Translation to the Future”, Chair Ground Rounds, Duke University Medical Center, Durham NC
- 6/13 “Translational Research in Acute Brain Injury: from Lab to Clinic”, Trinity College, Dublin, Ireland
- 5/13 “National VA/DOD Consortium in Traumatic Brain Injury”, Fort Detrick, MD
- 4/13 Translational approaches in the treatment of subarachnoid hemorrhage” , Stroke Conference, Duke University Medical Center, Durham, NC
- 5/12 “Genetic and Metabolic Stroke Syndromes”, Stroke Conference, Duke University Medical Center; Durham NC
- 10/11 “Development of a novel apoE-based therapy for acute brain injury”, Translational Neuroscience Symposium, Duke-NUS; Singapore
- 9/11 “Translational approaches in acute brain injury”, 2011 Society for Neurocritical Care Translational Science Symposium; Montreal, Canada
- 8/11 “New perspectives in the management of subarachnoid hemorrhage”, Anesthesiology Grand Rounds, Duke University Medical Center; Durham NC
- 8/11 “The role of the physician scientist in translational research”, Duke-NUS; Singapore
- 7/11 Workshop on US-China Stroke Research Collaborations, (invited), sponsored by National Institutes of Health/NINDS; Beijing China
- 5/11 “New research strategies in Diffuse Axonal Injury: role of HMG CoA reductase inhibitors” (invited), Workshop on Diffuse axonal injury sponsored by National Institutes of Health/NINDS; Bethesda, MD



- 9/10 Translational research in subarachnoid hemorrhage: the role of apolipoprotein E as a novel therapeutic strategy”, Inaugural Translational Research Symposium (speaker and moderator), Neurocritical Care Society; San Francisco, CA
- 6/10 Molecular mechanisms of ischemia and vasospasm in subarachnoid hemorrhage. (Grand Rounds), Wake Forest University School of Medicine; Winston Salem, NC
- 5/10 “Stroke biomarkers for risk prediction and diagnosis”, symposium on Translational Development Strategies in Acute Stroke, sponsored by Sanofi Aventis; Paris, France
- 4/10 27<sup>th</sup> Princeton Conference on Cerebrovascular Disease, “Neuroprotectants in Subarachnoid Hemorrhage”, (invited), Boston, MA
- 10/09 Advances in the management of patients with acute ischemic and traumatic brain injury, (Grand Rounds), Erlanger Hospital; Chattanooga, TN
- 9/09 NIH/NIA Workshop “Traumatic Brain Injury and the Risk of Dementia”, (invited), National Institutes of Health/NINDS, Bethesda, MD
- 4/09 Visiting scholar lecture series “Apolipoprotein E mimetics as a novel strategy for the treatment of neurological disease”; (invited) Cleveland Clinic, Cleveland, Ohio
- 3/09 “Evolving strategies for neuroprotection in the neurointensive care unit”, Baptist Medical Center; Asheville, NC
- 3/09 Distinguished Lecturer Seminar, “The neurobiology of apolipoprotein E in the injured CNS: translation to clinical therapeutic strategy”, Children’s Memorial Center, Northwestern Feinberg School of Medicine; Chicago IL
- 12/08 NIH Roundtable on the Advancing Emergency Stroke Research, “The role of biomarkers in the early diagnosis of Ischemic and Traumatic Brain Injury”, (invited), National Institutes of Health/NINDS; Bethesda, MD
- 10/08 “Apolipoprotein E based therapeutics”, (invited), 9<sup>th</sup> International Conference on Alzheimer’s Disease Drug Discovery; New York, NY
- 8/08 NIH workshop on the biology of apolipoprotein E, “ApoE: A Pharmacogenomic Therapeutic Target for Neurodegenerative Disorders”, (invited), National Institutes of Health/National Institute of Aging; Bethesda, MD
- 7/08 “Traumatic Brain Injury Consortium Research Program” (invited), NIH/Department of Defense; Bethesda, MD
- 2/08 NIH Workshop on Combination Therapies for Traumatic Brain Injury, “ The role of HMG CoA reductase inhibitors in traumatic brain injury: Translation from preclinical models to Clinical Trials”, (invited) National Institutes of Health/NINDS; Bethesda, MD
- 11/07 “From gene to therapy: Apolipoprotein E-mimetics in acute brain injury”,

- (invited), Society for Neurocritical Care; Las Vegas, NV
- 9/07 “Emergency management of Intracranial Hemorrhage”, Division of Emergency Medicine, Duke University Medical Center; Durham, NC
- 8/07 “Seizure management in neurocritical care: Prophylaxis and treatment”, Portsmouth Naval Base; Portsmouth, VA
- 3/07 “Treatment of hypertensive emergencies in intracranial hemorrhage and stroke”, Nash County Medical Society; Wilson, NC
- 3/07 “Levetiracetam exerts neuroprotective properties in translational paradigms of acute brain injury”, Neurology Grand Rounds, Forrest General Hospital; Hattiesburg, MS
- 2/07 “The role of HMG CoA Reductase Inhibitors in the acute management of SAH”, (invited faculty), presented for the AHA International Stroke Conference; San Francisco, CA
- 12/06 “Rationally derived apoE-mimetic therapeutic peptides: A new strategy in the treatment of Alzheimer’s disease”, presented for the Alzheimer’s disease Research Center, Duke University Medical Center; Durham, NC 27710
- 10/06 “Hemodynamic management of medical emergencies: Pathophysiology and management”, Neurology Grand Rounds, Forest Park Hospital; St. Louis, MO
- 9/06 “Translational research at Duke: Developing a novel therapy for subarachnoid hemorrhage from bench to bedside”, presented for Society of Clinical Research Associates; Durham, NC 27710
- 5/06 “Hypertensive Emergencies in Acute Ischemic Stroke: Pathophysiology and Management”, Neuroscience Grand Rounds, North Shore University Hospital; Manhasset, NY
- 4/06 “The use of biomarkers in the management of neonatal hypoxia/ischemia”, presented for the Neonatal/Perinatal Research Institute; Raleigh, NC
- 3/06 “Inflammation in the central nervous system: Implications for therapy after acute brain injury”, presented for Triangle Critical Care conference; Chapel Hill, NC
- 12/05 “Development of a novel therapeutic apoE-derived peptide for traumatic brain injury and subarachnoid hemorrhage”, Neuroscience Lecture Series, Medical College of Virginia; Richmond, VA
- 10/05 “Apolipoprotein E: the long road from gene to therapy”, Neuroscience Grand Rounds at Duke University Medical Center; Durham, NC
- 9/05 “The role of biomarkers in the diagnosis of stroke and subarachnoid hemorrhage”, (invited faculty), 4<sup>th</sup> International Conference on Biochemical Markers for Brain Damage; Booth Harbor, ME

- 8/05 “Estrogen and the role of selective estrogen receptor modulators in neuroprotection”, (invited faculty), Advancing the Study of Stroke in Women; Research Triangle Park, NC
- 6/05 “Clinical impact of a novel point of care diagnosis for stroke”, (invited), European Stroke Conference; Bologna, Italy
- 1/05 “Development of an novel therapeutic strategy for neuroprotection”, (invited), National Institute of Environmental Health; Raleigh, NC
- 11/04 “Use of a non-invasive stroke diagnostics as a surrogate endpoint for clinical neuroprotection trials”, (invited faculty), presented for the 7<sup>th</sup> International Conference on Neuroprotective Agents; Asilomar, CA
- 11/04 “New approaches to the rapid diagnosis of Acute Stroke”, (invited faculty), presented for the Institute of Advanced Medical Education National Tutorial on Stroke; Washington DC
- 10/04 “ApoE modulation of glial-mediated inflammation” (invited); presented for the Society for Neuroscience; San Diego, CA
- 7/04 “Stroke: Pathophysiology, Classification, and Epidemiology”, (invited faculty), presented for American Association for Clinical Chemistry; Los Angeles, CA
- 6/04 “The use of biochemical markers in stroke detection and management: evolving scientific evidence”, (invited symposium), presented for the World Stroke Conference; Vancouver, Canada
- 6/04 “The emerging role of biomarkers in cerebral ischemia: A translational initiative”, presented for Neuroscience Grand Rounds, Duke University School of Medicine; Durham, NC
- 3/04 “Management of cerebrovascular emergencies in the neurocritical care unit”, Baptist Medical Center; Wake Forest, NC
- 2/04 “The long road from gene to therapy: translational research and the development of an apoE-based therapeutic”, presented for Grand Rounds at the University of Pennsylvania; Philadelphia, PA
- 12/03 “New approaches to the rapid diagnosis of cerebral ischemia”, presented for the National Stroke Association; Orlando, FL
- 10/03 “Advances in Stroke Detection: Emerging role of biomarkers in stroke diagnosis”, presented for the American Association for Clinical Chemistry
- 9/03 “The role of apolipoprotein E and neurological disease: implications for novel treatment strategies, presented for Neuroscience Grand Rounds, University of North Carolina; Chapel Hill, NC

- 8/03 “Cerebral edema and the CNS inflammatory response: Pathophysiology and guidelines for management”, School of Nursing (Advanced Care Practitioner Series), Duke University Medical Center; Durham, NC
- 6/03 “A novel diagnostic test for cerebral ischemia”, presented for Stroke Conference, Duke University Medical Center; Durham, NC
- 4/03 “Translational aspects of glial cell biology”, presented for Neurology Research Conference, Duke University Medical Center; Durham, NC
- 10/02 “Cerebral ischemia: Diagnostic and therapeutic opportunities”, presented for Biosite Diagnostics; San Diego, CA
- 8/02 “From bedside to bench and back again: Is translational research a viable career?”, presented for the Duke University Medical School MSTP MD/PhD Training Program, Duke University Medical Center; Durham, NC
- 6/02 “Biochemical mechanisms underlying neuroinflammatory responses”, (invited colloquia), American Society for Neurochemistry; West Palm Beach, FL
- 2/02 “From bench to bedside: development of a translational research program in the Multidisciplinary Neuroprotection Laboratories”, presented for the Neonatal/Perinatal Research Institute, Duke University Medical Center; Durham, NC
- 1/02 “The role of apolipoprotein E and neurological disease: implications for novel treatment strategies”, presented for Neuroscience Grand Rounds, Duke University Medical Center; Durham, NC
- 11/01 “Apolipoprotein and Lipoprotein Receptors: Role in Development, Aging, and Disease”, (invited symposium), Society for Neuroscience; San Diego, CA
- 9/01 “Apolipoprotein E mimetic peptide is protective in a murine head injury model”, (invited symposium), American Neurological Association; Chicago, IL
- 7/01 “Apolipoprotein E: The long road from gene to therapy”, presented for the Department of Neurobiology, Duke University Medical Center; Durham, NC
- 5/01 “ApoE-mimetic peptides and cerebral ischemia: therapeutic potentials”, Cogent Neuroscience; Durham NC
- 4/01 “Therapeutic implications of apoE-mimetic peptides”, Biomeasure Inc.; Milford, MA
- 12/00 “Molecular genetics underlying CNS injury and Alzheimer’s Disease”, (invited symposium), Joint Plenary Session, American College of Veterinary Pathology; Amelia Island, FL
- 11/00 “Management of acute stroke”, presented at Sand Hills Community Hospital, NC

- 9/00 “Biochemical surrogates of acute ischemic brain injury (invited speaker), National stroke Association; Toronto, Canada
- 8/00 “Emergency evaluation and management of acute stroke”, presented at Fayetteville Regional Hospital, NC
- 5/00 “Stroke 2000: Advances in Treatment”, presented for the American Heart Association; Oklahoma City, OK
- 2/00 “Update on stroke prevention and therapy”, presented for the American Heart Association 11<sup>th</sup> Annual Triangle Update in Cardiology; Raleigh, NC
- 2/00 “Management of the patient with acute stroke”, presented for Grand Rounds Betsy Johnson Memorial Hospital; Dunn, NC
- 1/00 “Apolipoprotein E: An evolving role in the neurobiology of human disease”, presented for Medical Grand Rounds, Duke University Medical Center; Durham, NC
- 9/99 “ApoE and Neurological Disease”, presented for Neuroscience Grand Rounds, Duke University Medical Center; Durham, NC
- 6/99 “The Neurobiology of apolipoprotein E”, presented at Tel Aviv University; Tel Aviv, Israel
- 2/99 “Update in the management of acute stroke”, presented for Grand Rounds, Granville Medical Center; Oxford, NC
- 11/98 “Apolipoprotein E and acute brain injury”, presented at Cardiothoracic Anesthesia Conference, Duke University Medical Center; Durham NC
- 8/98 “Apolipoprotein E: neuroimmunological interactions in the brain”, (invited symposium) presented for the Sixth International Conference on Alzheimer’s Disease and Related Disorders; Amsterdam, Holland
- 7/98 “Thrombolytic therapy in the treatment of acute stroke”, presented at Grand Rounds, Louisburg Hospital; Louisburg, NC
- 6/98 “Apolipoprotein E and acute brain injury”, presented at Grand Rounds, Duke University Medical Center; Durham, NC
- 5/98 “Apolipoprotein E and the injured brain”, presented at the Stroke Research Symposium; Duke Center for Cerebrovascular Diseases; Durham NC
- 11/97 “Advances in the acute treatment of stroke”, presented for Grand Rounds, Morehead Hospital; Eden, NC
- 5/97 “Neuroimmunology of apolipoprotein E and recovery from acute brain injury”, presented for Glaxo-Wellcome; Stevanage, England

Areas of research interests (basic and applied) - list:

- Inflammatory mediators in acute CNS injury
- Therapeutic Development in TBI, ICH, and SAH
- Apolipoprotein E and the CNS response to injury
- Acute stroke/intracranial hemorrhage clinical trials
- Hypothermic neuroprotection
- Point of care diagnosis for CNS injury

External support - gifts, grants, and contracts:

**Past Support:**

**As Principle Investigator or Co-Principle Investigator**

Biogen-Idec, “ A multicenter, double blind, placebo-controlled, randomized, parallel-group study to evaluate the safety and efficacy of IV natalizumab on reducing infarct volume in acute ischemic stroke” (Site PI: Laskowitz)		
5% effort	11/1/2013-12/30/2015	\$206,175
Scion Pharma “Effect of Vestibular Stimulation on Cerebral Blood Flow in Normal Subjects” (PI: Laskowitz)		
5% effort	2/16/12-3/31/16	\$14,770
NIH/NINDS 1U01NS077964 “An Erythropoietin-Mimetic Peptide for treatment of TBI(PI: Roberston, Duke PI: Laskowitz)		
10% effort	9/1/2013-7/31/2015	
AHA 14POST20380435 “Translation of a neuroprotective apolipoprotein E mimetic” (PI/mentor: Laskowitz; post-doc Kernagis)		
<5% effort	7/1/2014-6/30/2016	\$100,000
NIH/NINDS4U44NS071657-02 “Development of a pH dependent NMDA Neuroprotectant for treatment of cerebral ischemia” (PI: Koszalka; Duke PI: Laskowitz)		
10% effort	4/1/13-12/31/14	
BHR “Phase 3 Double-Blind Study to determine the safety and Efficacy of Progesterone in Patients with severe Traumatic Brain Injury” (Site PI: Laskowitz)		
5% effort	10/13/11-5/1/14	\$92,898
Astute Medical, “Sample Collection Study to Evaluate Novel Biomarkers from Acutely Ill Patients at Risk for Acute Kidney Injury (PI: Kolls, Laskowitz)		
5% effort	6/24/08-6/23/14	\$600,000
Wallace H. Coulter Foundation “Linearized apoE peptides are neuroprotective in acute brain injury” (PI: Laskowitz, Bass)		
10% effort	7/1/11-6/30/13	\$300,000
UCB Pharma “Lacosamide improves outcomes after closed head injury and subarachnoid hemorrhage” (PI: Laskowitz)		

10%	1/1/11-12/31/13	\$154,604
Transition Therapeutics “Translational protocol development for TT-301, a novel modulator of microglial activation” (PI: Laskowitz)		
5% effort	9/1/10-8/31/11	\$120,000
NIH/NINDS R34NS06465-01A1 “Therapeutic for Intracranial Hemorrhage” (SBIR sponsor: Cognosci; Duke PI: Laskowitz)		
10% effort	6/1/09- 5/31/11	\$68,119
AHA “Inflammatory genetic influences in human intracerebral hemorrhage” (PI: James; Mentor: Laskowitz)		
<5% effort	7/1/2009-6/30/2011	\$135,000
Foundation for Anesthesiology Research “Pharmacogenomic Influences of ApoE and Mimetic Peptides on Neurological Outcomes as a Paradigm for Targeted Therapeutic” (PI: James; Mentor: Laskowitz)		
<5% effort	7/1/2009-6/30/2011	\$190,000
IRUSROSU024 Astra-Zeneca “The use of rosuvastatin in preclinical models of acute brain injury (PI: Laskowitz)		
5% effort	6/1/09-12/31/09	\$10,000
Institute for the Study of Aging “The effect of apoE-mimetic peptide in a murine model of AD” (PI: Laskowitz)		
25% effort	6/1/08-5/31/09	\$97,364
Roche Biomedical Laboratories “Elecsys S100 as a Biochemical Surrogate of Mild Traumatic Brain injury: A Prospective Study” (PI: Laskowitz/Grant)		
5% effort	6/1/08-5/31/10	\$92,527
NIH/NINDS 1R41NS056856-01A2, Evaluation of pH Dependent Neuroprotectants in SAH Model” (PI: Laskowitz)		
	7/1/08-6/31/10	\$30,936
NIH 1UL1 RR024128-01 (DTRI) “Clinical and Translational Science Award: Exploratory Investigational New Drug Application for Phase O Human Clinical Trial of a Novel Treatment for Traumatic Brain Injury” (PI: Laskowitz/Vitek)		
10% effort	4/1/07-3/30/08	\$145,426
Institute for the Study of Aging “The effect of apoE-mimetic peptide in a murine model of AD” (PI: Laskowitz)		
25% effort	3/1/07-2/28/08	\$97,364
NIH 1UL1 RR024128-01 (DTRI) “Clinical and Translational Science Award: 3D Ultrasound scanner for combined diagnosis and therapy of stroke” (PI: Laskowitz/Smith)		
5% effort	4/1/07-3/30/08	\$120,000
NIH/NINDS R44 ND47592 “Enhancing Peptide Delivery to the Brain (SBIR sponsor: Cognosci; Duke PI: Laskowitz)		
10% effort	10/1/05-11/30/09	\$324,621

Bristol Myer Squibb “Use of echocontrast to enhance transcranial duplex imaging” (PI: Laskowitz) 5% effort	10/01/07-9/31/08	\$21,126
NIH/NIA R44AG020473 “Neuroprotective apolipoprotein E analogs” (SBIR sponsor: Cognosci; Duke PI: Laskowitz) 10% effort		
Transition Therapeutics “Novel anti-inflammatory agent for treatment of TBI and SAH” (PI: Laskowitz) 10% effort		
NIH/NINDS 2R44 NS43954 “Novel Tissue Protector for Subarachnoid Hemorrhage” (STTR sponsor: Cognosci; Academic PI: Laskowitz) 20% effort	1/1/06-12/31/07	\$154,800
Biosite Diagnostics “Novel Diagnostic Markers for acute Stroke” (PI: Laskowitz) 10% effort	7/1/05-6/30/07	\$351,356
Institute for the Study of Aging “The effect of apoE-mimetic peptide in a murine model of AD” (PI: Laskowitz) 25% effort	9/1/05-8/31/06	\$207,364
NIH/NINDS R21NS4487-01 “Pharmacogenomic interactions between apoE mimetic peptide and genetic background in a murine model of head injury” (PI: Laskowitz) 20% effort	7/1/03-6/30/05	\$378,000
NIH/NINDS 2R44 NS43954 “Identification of neuroprotective apoE-mimetics” (PI: Vitek; PI Duke subcontract: Laskowitz) 10% effort	10/1/02-9/30/05	\$184,800
NIH/NINDS 1 RO1 NS368087-01A2 “Characterization of a microglial- specific toxin” (PI: Laskowitz) 10% effort	3/1/99-2/28/04	\$508,039
American Federation of Aging Research “Apolipoprotein E, microglial activation, and neurodegenerative disease” (PI: Laskowitz) 10% effort	7/1/99-6/30/04	\$449,999
Merck, Inc. “Simvastatin ameliorates vasospasm following subarachnoid hemorrhage” (PI: Laskowitz/Lynch) 5% effort	7/1/02-6/30/04	\$100,000
NIH/NINDS 1K08NS01949-S1 (Competitive supplement) “The effect of apolipoprotein E on the CNS immune response” (PI: Laskowitz) 60% effort	8/30/01-9/1/03	\$216,000



NIH/NINDS 1R43NS45421-01A1 “Novel Inhibitors of Brain Ischemia” (PI of SBRI subcontract: Laskowitz)	9/1/03-8/31/03	\$30,800
NIH/NINDS 1K08NS01949 “The effect of apolipoprotein E on the CNS immune response” (PI: Laskowitz) 60% effort	7/1/98-6/30/01	\$269,850
NIH/NIA 1 RO3 AG16507-01 “Microglial activation pathways: regulation by apoE” (PI: Laskowitz) 7% effort	5/99-4/31/00	\$50,000
NIH/NIA 1R43AG/MH17789 “Identification of Neuroprotective ApoE-mimetics” (PI: Vitek/Laskowitz) 3% effort	9/00-3/01	\$100,000
Medivance, Inc “Prospective clinical study evaluating safety and feasibility of surface cooling for acute ischemic stroke (PI: Laskowitz/Graffagnino)” 3% effort	7/01-6/02	\$10,000
NIH/NIA 2P50 AG05128 “Pilot Grant: Apolipoprotein E and the CNS response to injury” (PI: Laskowitz) 5% effort	5/1/00-4/30/01	\$30,000
Biosite Diagnostics “Unrestricted educational grant for biomarkers of brain injury” (PI: Laskowitz) 5% effort	7/1/03-6/30/02	\$20,000
Biosite Diagnostics “Serum markers of brain injury” (PI: Laskowitz/Grocott) 5% effort	9/1/00-8/31/01	\$167,313
Biosite Diagnostics “Substudy: Peripheral markers of Alzheimer’s Disease” (PI: Laskowitz) 5%effort	1/01/01- 6/30/01	\$19,800
Biosite Diagnostics “Serum markers of brain injury” (PI: Laskowitz/Grocott) 5% effort	9/1/99-8/31/00	\$149,281
Culpeper Foundation “Apolipoprotein E-derived peptides modulate glial function” (PI: Laskowitz) 5% effort	9/1/98-8/31/99	\$25,000
National Stroke Association, “Apolipoprotein E and Cerebral Ischemia” (PI: Laskowitz) 15% effort	7/1/97-6/30/99	\$60,000
Smith-Kline Beecham “Anti-platelet Useful Dose Study” (PI: Graffagnino/Laskowitz) 20% effort	1997-1998	\$10,000
American Association of Neurology/Genentech Young Investigator Award (PI: Laskowitz) 30% effort	7/1/97-6/30/98	\$50,000

National MS Foundation “Apolipoprotein E and Multiple Sclerosis” (PI: Laskowitz)  
 10% effort 7/1/97-6/30/98 \$25,000

**As a participating Investigator**

U01-FD0084858 Clinical Practice Data to Aid Narrow Therapeutic Index Drug Classification  
 (PI: Cohen-Wolkowicz)  
 5% effort 9/15/13- 3/31/16 \$157,340

American Heart Association - Bugher Foundation AHA 0775001N “Small Vessel Intracranial  
 Disease: Whole Genome Association Studies” (PI: Goldstein)  
 10% effort 07/01/07-06/30/12 \$1,007,445

NIHT32-GM007171-35 “Medical Scientist Training Program” (PI: Kontos)  
 <5% effort 7/1/07-6/30/12 \$1,487,000

NIH R25NS09-001 NINDS “Research Education Programs for Residents and Fellows in  
 Neurology and Neurosurgery” (PI: Sampson)  
 <5% effort 07/1/09-6/30/13

TBI/PTSD Clinical Consortium Study Site (PI: Grant, Gerald) \$334,153  
 10% effort 09/15/2008 – 09/14/2014

Alzheimer Association IIRG-07-59655 “Novel therapeutic reduces A $\beta$  deposition and Alzheimer’s  
 pathology” (PI: Vitek)  
 10% Effort 10/1/07-9/30/10 \$218,181

NIH T32-HD043728-03 Multidisciplinary Neonatology Training (PI: Goldberg)  
 <5% Effort 05/01/05 - 04/30/10

Department of Defense/UCSD “Randomized Controlled Trial of Galantamine, Methylphenidate, and  
 Placebo for the Treatment of Cognitive Symptoms in Patients with Mild Traumatic Brain Injury  
 (mTBI) and/or Posttraumatic Stress Disorder (PTSD)” (PI: Grant)  
 4% effort 8/1/11-7/31/13

American Heart Association “Safety and Clinical Effectiveness of Intravenous Tissue Plasminogen  
 Activator for Acute Ischemic Stroke” (PI: Xian)  
 2% effort 1/1/13-12/31/14 \$70,000

Department of Defense PTO75560 “TBI/PTSD Clinical Consortium Study Site”  
 (PI: Grant/Marx)  
 5% effort 6/1/08-5/31/13 \$1,473,715

HU0001-11-1-TS07 N11-P15 Department of Defense/Uniformed Service Univ. “Unmasking  
 cognitive deficits after recovery from mild traumatic brain injury” (PI: Vacchiano)  
 5% effort 8/1/11 – 7/31/14 \$497,616

NIH/NINDS R01NS40406, “Albumin in Acute Stroke (ALIAS) Trial” (PI: Ginsberg/Duke Site PI:  
 Laskowitz)  
 <5% effort 7/1/09-6/30/10

NIH/NIA 1 R01AG19780 “Triple transgenic model of Alzheimer’s Disease” (PI: Vitek)  
16% effort 6/15/02-5/31/07 \$1,212,500

NIH RO1- HL69081-01, “PeriOperative Interventional Neuroprotection Trial”  
(PI: Mark F. Newman)  
5% effort 12/01/01 – 11/30/06 \$552,597

1 RO1 AG16762-05 “Genetics, Inflammation and Post-op Cognitive Dysfunction”  
(PI: Newman)  
5% effort 9/30/99-7/31/04 \$1,073,620

AHA “A randomized double blind placebo-controlled study of neuroprotection with lidocaine in  
cardiac surgery” (PI: Newman)  
3% effort 3/1/1999-2/28/02 \$500,000

NIH/NINDS RO1NSAG37235 “ApoE and the Ischemic Brain” (PI: Warner)  
3% effort 3/1998-2/2002 \$778,688

**Present Support:**

**As Principle Investigator or Co-Principal Investigator**

DOD CDMRP#W81XWH-16-C-0142 Prophylactic administration of CN-105 confers  
neuroprotection against acute brain injury (PI: Laskowitz)  
30% effort 9/30/2016- 12/29/17 \$401,138

Astra-Zeneca, “Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and  
Patient Outcomes (SOCRATES)” (PI: Laskowitz)  
5% effort 9/4/2014- 6/30/2016 \$2,710,099

NIH 1D43-TW008308-01 “Training for the prevention and treatment of stroke” (PI: Laskowitz)  
10% effort 7/1/10-3/30/17 \$704,960

NC Biotechnology Collaborative Funding Grant “Neuroprotective peptides improve outcome after  
ischemic stroke and subarachnoid hemorrhage” (PI: Laskowitz)  
5% effort 7/1/14-6/20/2016 \$160,000

**As a participating Investigator**

NIH/NINDS 1K23-NS085049-01A1 “Immunological biomarker studies in myasthenia gravis:  
(PI: Guptill; Mentor, Laskowitz)

<5% effort	07/01/2014 - 06/30/2019	\$165,251
NINDS Clinical Trials for Development of Neurotherapeutics Performance Area A (PI: Krystal) 5% effort	07/01/2016 – 06/30/2026	\$2,067,095
Marcus Foundation “Allogenic Cord Blood Stroke Program” (PI: Kurtzberg) 5% effort	7/1/15-6/30/17	\$142,00
NIH/NIN Center for Adaptive Leadership in Cognitive Affective Symptoms in Science (PI: Reuter Rice)	9/26/12-6/30/17	
NIH 1P30-NR014139-01 Physiologic Adaptation and Neurocognitive Outcomes in Pediatric Traumatic Brain Injury (PI: Reuter-Rice) 5% effort	9/26/12-6/30/17	\$50,626
NIH T32 GM008600-01 “Integrated Training In Anesthesiology Research” (PI: Warner) <5% effort	7/1/011-6/30/16	\$192,826
USUHS Investigator Initiated Award (HU0001-11-1-TS07 N11-P15, (PI: Vacchiano) 5% effort	08/01/2011 - 07/31/2016	\$552,226

**Pending Support:**

**As Principle Investigator or Co-Principal Investigator**

**As a participating Investigator**

CURE AD “A novel therapeutic intervention to slow AD pathology in a preclinical murine model”	12/1/2016-11/30-2017	\$145,000
1R01-NR016222-01A1 Genetic Polymorphisms that Predict Outcomes in Children with Severe Traumatic Brain Injury (sTBI)	07/01/2016 – 06/30/2021	\$375,543

**Clinical activity - type of practice and estimate of time commitment:**

Attending, (Neurointensive Care Unit, outpatient clinic): 20%  
 Inpatient Stroke Service, Consult Attending, MOPC clinic, TCD reading schedule: 20%  
 Administrative (Includes Director of Neurovascular Laboratory, Associate Director  
 of Multidisciplinary Neuroprotection Laboratories, and Chair of the 3<sup>rd</sup> Year Committee for  
 the Medical School; Vice Chair for Research and Faculty Development ): 20%  
 Teaching: 15% (undergraduate students and medical students in lab, mentor for stroke and  
 ICU fellows, resident preceptor, resident lectures, medical student lectures)  
 Research: 35% (laboratory based and clinical research; A faculty at DCRI)

**Participation in academic and administrative activities of the University and Medical Center:**

Advisory Board, Neurology Clinical Research Organization

Director, CNS Therapeutics at DCRI

Neurology Residency Selection Committee

Medical Director, Neurovascular Laboratories

Associate Director, Multidisciplinary Neuroprotection Laboratories

Third Year Director, Duke University Medical School (25% effort)

Curriculum Committee, School of Medicine

Curricular Administrative Group, School of Medicine

Vice-Chair Research and Academic Development, Department of Neurology